(1	9

(12)

Europäisches Patentamt European Patent Office Office européen des brevets



(11) **EP 2 881 461 A1**

EUROPEAN PATENT APPLICATION

(43) Date of publication: (51) Int Cl.: C12N 5/071 (2010.01) 10.06.2015 Bulletin 2015/24 (21) Application number: 14192115.5 (22) Date of filing: 21.11.2008 (84) Designated Contracting States: Arnold, Antje AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 04107 Leipzig (DE) HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT · Brown, Jeremy **RO SE SI SK TR** Falmouth, Cornwall TR11 3EW (GB) (62) Document number(s) of the earlier application(s) in (74) Representative: Kilger, Ute accordance with Art. 76 EPC: **Boehmert & Boehmert** 08400048.8 / 2 192 174 Anwaltspartnerschaft mbB Patentanwälte Rechtsanwälte (71) Applicant: Fraunhofer-Gesellschaft zur Förderung Pettenkoferstrasse 20-22 80336 München (DE) der angewandten Forschung e.V. 80686 München (DE) Remarks: This application was filed on 06-11-2014 as a (72) Inventors: divisional application to the application mentioned under INID code 62. · Stolzing, Alexandra 04103 Leipzig (DE)

(54) Reprogramming cells toward a pluripotent state

(57) The present invention relates to a process for preparing reprogrammed cells, in particular for preparing pluripotent and multipotent stem cells and to the pluripotent and multipotent stem cells prepared by said processes.

Description

[0001] The present invention relates to a process for preparing reprogrammed cells, in particular for preparing pluripotent and multipotent stem cells and to the pluripotent and multipotent stem cells prepared by said processes.

⁵ [0002] Aging - whether in vivo during the life course or in vitro during scale up - affects cells, in particular stem cells. For example, aged cells show increased apoptosis rates, decreased differentiation and proliferation capacity, and decreased therapeutic effectiveness. During aging, stem cells often differentiate into a less pliable, less proliferative form. Cell aging represents a problem in particular when using cells from elderly patients/donors as starting material for cell cultures, when expanding cells in vitro and when using cells that have a limited differentiation capacity for therapy or research.

[0003] One approach to dedifferentiate aged cells is to create so called Induced Pluripotent Stem Cells (IPS). The current state of the art foresees to use a viral transfer of transcription factors to induce increased differentiation potency in cells and to rejuvenate them. This, however, is potentially dangerous because a viral transfer permanently changes the genome of the cell and also might lead to complications because of the viral parts left behind in the cell genome.

¹⁵ Moreover, viral integration into the genome is known to increase cancer risk in cells. Essentially the same applies to the use of plasmids for reprogramming cells (Okita et al., 2008, Science. 2008 Nov 7;322(5903):949-53. Generation of mouse induced pluripotent stem cells without viral vectors).

[0004] Another approach employs contacting cells to be reprogrammed with extracts of human embryonic stem cells for reprogramming cells. This approach, however, is ethically and practically problematic.

- 20 [0005] Some other approaches use chemical factors to dedifferentiate cells (e. g. US 200710254884 A1, US 200710020759 A1), but these factors are not efficacious in fully reprogramming cells to a pluripotent state by themselves. [0006] Thus, the technical problem underlying the present invention is to provide improved methods to reprogram cells, in particular to dedifferentiate cells, which overcome the above-identified disadvantages, in particular allow in an easy, efficient and safe way the provision of reprogrammed, in particular dedifferentiated cells, preferably displaying multipotent most preferably pluripotent stem cell character.
- ²⁵ multipotent, most preferably pluripotent, stem cell character. [0007] The present invention solves its technical problem by the provision of a process for preparing reprogrammed cells in vitro, comprising the process steps, preferably in the given order, a) providing cells to be reprogrammed; b) introducing, preferably transfecting, mRNA molecules capable of reprogramming the cells into the cells provided in step a), wherein the reprogramming mRNA molecules are coding for at least one protein selected from the group consisting
- ³⁰ of: Ronin, Oct4, Klf4, Sox2, Nanog and TERT; and c) culturing the cells obtained in step b) in a cell culture medium and under a condition suitable to allow translation of the introduced, preferably transfected reprogramming mRNA molecules so as to obtain reprogrammed cells.

[0008] Thus, the present invention foresees a process which is able to prepare reprogrammed cells without the need to permanently change the genome of the cell and without the need to use viruses to transfer transcription factors or

- ³⁵ the like into the cell. The present invention also is advantageous in so far, as for reprogramming cells no extracts of human embryonic stem cells or cost intensive and potentially dangerous chemical factors are needed. Thus, ethical concerns, genetic stability problems and cancer risks are reduced or even avoided. In contrast, the present invention provides the advantageous teaching to introduce, preferably transfect, specific mRNA molecules, in the following termed "reprogramming mRNA molecules", into the cells, wherein these reprogramming mRNA molecules are able to reprogram
- 40 the mRNA recipient cells, preferably the cells being transfected therewith, into a dedifferentiated status. Advantageously, the mRNA molecules introduced, preferably transfected, according to the present invention will not integrate into the recipient's genome and therefore do not pose a risk of cancer or genetic instability. The invention therefore foresees a process for preparing one or more reprogrammed cells in vitro wherein said process does not include any cloning amplification or proliferation of the mRNA recipient cells. The present invention also foresees a process for preparing
- ⁴⁵ one or more reprogrammed cells in vivo, that is in a living organ, a living organism or animal, more particular a mammal. [0009] In the context of the present invention the term "reprogramming" preferably means remodelling, in particular erasing and/or remodelling, epigenetic marks of a cell such as DNA methylation, histon methylation or activating genes by inducing transcription factor signal systems as for oct4. In particular, the reprogramming of the present invention provides at least one dedifferentiated and/or rejuvenated cell, in particular provides a cell having the characteristic of a
- ⁵⁰ multipotent, in particular pluripotent stem cell. Thus, in case the cell to be reprogrammed is cells which already have a multipotent or pluripotent character, the present invention is able to maintain these cells by the reprogramming of the present invention in their multi- or pluripotent state for a prolonged period of time. In case the cells to be reprogrammed are in an aged or differentiated state, the present invention allows the dedifferentiation into a multipotent or pluripotent stem cell. In a particularly preferred embodiment, multipotent cells may be reprogrammed to become pluripotent cells.
- ⁵⁵ **[0010]** In particular, the term "reprogrammed cells" designates cells which have been changed to have a higher differentiation and/or proliferation potential. Also, in a preferred embodiment the reprogramming of asomatic differentiated cell toward a multipotent stem cell or "young" differentiated cell is termed reprogramming and the product is called a reprogrammed cell.

[0011] In particular, the present process allows it to enrich immature stem cells, preferably showing a high telomerase activity, several multipotent, preferably pluripotency, markers and an increased secretion of growth factors. The present invention provides the advantage that aged stem cells can be expanded for a longer period of time and with a higher stem cell yield. Further, stem cell lines and tissue engineered construct drafts made or derived from cells reprogrammed

- ⁵ by the present process show a reduced minimal immunological risk, in particular if the patient owns cells are used as a source for the reprogramming. Thus, the present invention provides means and methods to prepare in particular pluripotent stem cells, to provide multipotent stem cells, to provide means and methods for an increased expansion of cells or stem cells in vitro and for the rejuvenation of aged cells or aged stem cells for tissue engineering or cell therapies. [0012] In particular, the present invention foresees, preferably in a first step, to provide cells to be reprogrammed.
- Preferably, the cells to be reprogrammed may be adult, neonatal or embryonic differentiated cells, but are not limited thereto. Preferably, the cells to be reprogrammed are adult or neonatal undifferentiated cells. All of these cells may, in a preferred embodiment, be cell lines, immortalized cells, cells kept in cell culture, isolated cell populations, preferably cells isolated from a donor, either a living or dead donor, or cells isolated from the environment. Cell types which can be reprogrammed according to the present invention potentially are all cell types, and are in preferred instances fibrob-
- ¹⁵ lasts, hepatocytes, cardiac cells, cardiomyocytes, nerve cells, chondrocytes, osteoblasts, adipocytes, myoblasts, hepatoblasts, hepatic stem cells, insulin producing cells, neural stem cells, cardiomyogenic cells, dermatocytes, keratinocytes, pancreatic cells, monocytes, epithelial cells or mesenchymal stem cells (MSC). Preferably, the cells may be mammalian cells, in particular human cells or animal cells, preferably ovine, horse, ape or in particular rodent cells, preferably hamster cells, mouse cells or rat cells. The cells may also be fish, reptile, avian, amphibian or insect cells. Preferably, the cells
- to be reprogrammed are lineage-committed cells. In a further preferred embodiment the cells, in particular the cells of the above identified origin, are stem cells, in particular post-natal stem cells or non-embryonic stem cells.
 [0013] A suitable and preferred stem cell source like mesenchymal stem cells is a tissue within the human or animal body which comprises the stem cells for use in the present invention, optionally together with other cell types. Preferably, the suitable stem cell source is bone marrow, both adult and fetal, cytokine or chemotherapy mobilized peripheral blood,
- fetal liver, umbilical cord blood, embryonic yolk sac and spleen, both adult and fetal, more preferably the stem cell source is adult bone marrow or umbilical cord blood, most preferably the stem cell source is bone marrow. Bone marrow cells may be obtained from any known source, including, but not limited to, ilium, sternu, tibiae, femora, spine or other bone cavities. Preferably, the stem cells are isolated from a mammalian organism such as human, mouse or rat, and more preferably the stem cells are isolated from a human organism.
- 30 [0014] The term "isolated cell population" is intended to mean that the cells are not in contact with other cells with which they are usually in contact within the body of the mammal or in a tissue sample obtained directly, i.e. without purification or enrichment step, from the mammal. A "cell population" according to the present invention may comprise not only cells of one cell type such as fibroblasts or mesenchymal stem cells as defined for example by the expression of a specific combination of surface markers, but also a mixture of cells of different cell types which show different combinations of surface markers.
 - **[0015]** The cells harvested from said sources may be used directly for transfection or may be cryoconserved by freezing them at a temperature from about 196 °C to about 130°C.

[0016] The cells to be reprogrammed receive, according to the present invention, in a second step at least one species of reprogramming mRNA molecules, in particular linear and isolated mRNA molecules, selected from the group of mRNA molecules encoding Ronin, mRNA molecules encoding Oct4, mRNA molecules encoding Klf4, mRNA molecules encoding Sox2, mRNA molecules encoding Nanog and mRNA molecules encoding TERT. Ronin, Oct4, Klf4, Sox2, Nanog and TERT are proteins with the ability to reprogram cells. In the context of the present invention these proteins are termed "reprogramming proteins" and are characterised by their ability to reprogram target cells and therefore by their regulatory function in terms of determining the cell fate, in particular being able to dedifferentiate a target cell and/or

- ⁴⁵ maintain a cell in a dedifferentiated state, preferably by being transcription factors.
 [0017] Differentiation behaviour of cells and state of differentiation can be detected according to the methods set forth below. However any method for determining the differentiation state or potency of a cell known the skilled person are applicable as well.
- [0018] In a preferred embodiment, the cell to be reprogrammed is transfected with one or more reprogramming mRNA molecules according to the present invention. In another preferred embodiment the cell to be reprogrammed is supplemented with one or more reprogramming mRNA molecules according to the present invention. In another preferred embodiment the cell to be reprogrammed is injected with one or more reprogramming mRNA molecules according to the present invention. In another preferred embodiment the cell to be reprogrammed is injected with one or more reprogramming mRNA molecules according to the present invention.
 - [0019] The present invention thus foresees to use one or more of mRNA molecules encoding Ronin, Oct4, Klf4, Sox2,
- ⁵⁵ Nanog or TERT. These mRNA molecules may, in a preferred embodiment, be molecules having the wild-type mammalian, in particular human, animal, preferably rodent, more preferably mouse, hamster or rat or any other animal nucleotide sequence. In a preferred embodiment of the present invention the reprogramming mRNA molecule is selected from the group consisting of mRNA nucleotide sequence molecules being encoded by any one of the DNA sequences given

under SEQ ID No. 1 to 16.

[0020] Of course, the invention also foresees to use mRNA molecules, whose sequence is a functional equivalent to the polynucleotide sequence given above. In the context of the present invention a functional equivalent is a nucleotide sequence molecule, which either codes with a different nucleotide sequence exactly the same protein as the mRNA

5 sequence encoded by any one of SEQ ID No. 1 to 16 or is a mRNA sequence, which encodes a protein with a different amino acid sequence but with same or similar function, in particular being able to reprogram the cells according to the present invention.

[0021] In a particularly preferred embodiment of the present invention the functional equivalent of the mRNA molecules is a polynucleotide with a homologous sequence to the wild-type mRNA polynucleotide as encoded by the DNA sequence

- 10 in any one of SEQ ID No. 1 to 16. In a preferred embodiment of the present invention the degree or percentage of homology is at least 50, 60, 70, 80, 90, 95, 99 or 100%. In a furthermore preferred embodiment a functional equivalent of the mRNA molecules as given in any one of SEQ ID No. 1 to 16 is a mRNA sequence which is encoded by a DNA sequence being substantially complementary to the sequences of any one of SEQ ID No. 1 to 16 or to its complementary, preferably substantially, complementary sequence. In a furthermore preferred embodiment the functional equivalent of
- 15 the mRNA molecule as encoded by any one of the DNA sequences of SEQ ID No. 1 to 16 is a mRNA molecule being encoded by a DNA sequence which is able to hybridize under stringent or reduced stringent conditions to any one of the polynucleotides given in SEQ ID No. 1 to 16 or to its complementary, preferably substantially, complementary sequence.

[0022] In the context of the present invention the term "mRNA molecule" is meant to refer to a linear polymer of ribonucleotide molecules, which is single-stranged and serves as a template for protein synthesis.

[0023] Polynucleotides have "homologous" sequences if the sequence of nucleotides in the two sequences is the same when aligned for maximum correspondence as described herein. Sequence comparison between two or more polynucleotides is generally performed by comparing portions of the two sequences over a comparison window to identify and compare local regions of sequence similarity. The comparison window is generally from about 20 to 200 contiguous

25 nucleotides.

20

[0024] The "percentage of sequence homology" for polynucleotides, herein referred to be 50, 60, 70, 80, 90, 95, 98, 99 or 100 percent sequence homology, may be determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may include additions or deletions (i.e. gaps) as compared to the reference sequence (which does not comprise additions or deletions) for

- 30 optimal alignment of the two sequences. The percentage is calculated by: (a) determining the number of positions at which the identical nucleic acid base occurs in both sequences to yield the number of matched positions; (b) dividing the number of matched positions by the total number of positions in the window of comparison; and (c) multiplying the result by 100 to yield the percentage of sequence homology. Optimal alignment of sequences for comparison may be conducted by computerized implementations of known algorithms, or by inspection. Readily available sequence com-
- 35 parison and multiple sequence alignment algorithms are, respectively, the Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. 1990. J. Mol. Biol. 215:403; Altschul, S.F. et al. 1997. Nucleic Acid Res. 25:3389-3402) and ClustalW programs both available on the internet. Other suitable programs include GAP, BESTFIT and FASTA in the Wisconsin Genetics Software Package (Genetics Computer Group (GCG), Madison, WI, USA).
- [0025] As used herein, "substantially complementary" means that two nucleic acid sequences in question have at 40 least about 65%, preferably about 70%, more preferably about 80%, even more preferably 90%, and most preferably about 98%, sequence complementarity to each other. This means that the DNA sequence coding the functional equivalent and the polynucleotide given in any of SEQ ID No. 1 to 16 or its complement must in a preferred embodiment exhibit sufficient complementarity to hybridise under stringent conditions. A substantially complementary sequence is preferably one that has sufficient sequence complementarity to the nucleotide sequence in question to result in binding.
- 45 [0026] The term "primer" as used herein refers to an oligonucleotide which is capable of annealing to the amplification target allowing a DNA polymerase to attach thereby serving as a point of initiation of DNA synthesis when placed under conditions in which synthesis of primer extension product which is complementary to a nucleic acid strand is induced, i.e., in the presence of nucleotides and an agent for polymerization such as DNA polymerase and at a suitable temperature and pH. The (amplification) primer is preferably single stranded for maximum efficiency in amplification. Preferably, the
- 50 primer is an oligodeoxy ribonucleotide. The primer must be sufficiently long to prime the synthesis of extension products in the presence of the agent for polymerization. The exact lengths of the primers will depend on many factors, including temperature and source of primer.

[0027] A "pair of bi-directional primers" as used herein refers to one forward and one reverse primer as commonly used in the art of DNA amplification such as in PCR amplification.

55 [0028] The terms "stringency" or "stringent hybridization conditions" refer to hybridization conditions that affect the stability of hybrids, e.g., temperature, salt concentration, pH, formamide concentration and the like. These conditions are empirically optimised to maximize specific binding and minimize nonspecific binding of an oligo- or polynucleotide to its target nucleic acid sequence. The terms as used include reference to conditions under which an oligo- or polynucleotide will hybridise to its target sequence, to a detectably greater degree than other sequences (e.g. at least 2-fold over background). Stringent conditions are sequence dependent and will be different in different circumstances. Longer sequences hybridise specifically at higher temperatures.

[0029] Generally, stringent conditions are selected to be about 5 DEG C (degree celcius) lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength and pH) at which 50% of a complementary target accuracy by bridings to a perfectly metabolic direction.

5

35

- ionic strength and pH) at which 50% of a complementary target sequence hybridises to a perfectly matched oligo- or polynucleotide. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M Na <+> ion, typically about 0.01 to 1.0 M Na <+> ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30 DEG C for short probes or primers (e.g. 10 to 50 nucleotides) and at least about 60 DEG C for long
 probes or primers (e.g. greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of
- probes or primers (e.g. greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.
 [0030] Exemplary low stringent conditions or "conditions of reduced stringency" include hybridization with a buffer solution of 30% formamide, 1 M NaCl, 1% SDS at 37 DEG C and a wash in 2x SSC at 40 DEG C. Exemplary high
- stringency conditions include hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37 DEG C, and a wash in 0.1x
 SSC at 60 DEG C. Hybridization procedures are well known in the art and are described in e.g. Ausubel et al, Current Protocols in Molecular Biology, John Wiley & Sons Inc., 1994.
 [0031] Thus, the present invention foresees to introduce, preferably transfect, specific reprogramming mRNA molecules into the cells, which mRNA molecules once introduced, preferably transfected, in the cells are able to be translated
- into so called reprogramming proteins which can turn on specific genes in the cells, in particular multipotency and/or the pluripotency genes in the cell. The mRNA molecule used according to the present invention is preferably a linear molecule having a poly A tail, most preferably produced by in vitro transcription. Thus, in a preferred embodiment the mRNA molecules are produced by in vitro transcription, in particular using bacterial systems. In a particular preferred embodiment the DNA sequences of the reprogramming proteins are cloned into plasmids and amplified in bacteria, for instance E. coli. In a further preferred embodiment, the plasmids are then isolated from the bacteria, are linearised and subjected
- to restriction digestion. In a further preferred embodiment cDNA prepared by said method is transcribed into mRNA, which in turn is incubated to destroy cDNA residues and to obtain mRNA molecules to be introduced into the cells. [0032] Since the introduced reprogramming mRNA molecules and the proteins translated therefrom are over the time being degraded in the cells, they cannot permanently integrate into the genome of the cell providing some of the advantageous features of the present invention.
- ³⁰ **[0033]** In a preferred embodiment of the present invention the present teaching foresees to introduce, preferably transfect, the reprogramming mRNA molecules into the cell by electroporation, by lipofection, by injection, by magneto-fection, by particle bombardment, gene gun, or by any other method known in the art suitable to introduce mRNA molecules into a target cell.

[0034] In a particular preferred embodiment the present invention further foresees in its step c) to culture the cells into which the reprogramming mRNA molecules have been introduced in a cell culture medium and under a condition suitable to allow translation of the transfecting reprogramming mRNA molecules, so as to obtain the reprogrammed cells.

- [0035] In a particularly preferred embodiment of the present invention the present process therefore consists of the above-identified steps a), b) and c), preferably in this order. Accordingly, the present invention excludes any further process steps, in particular any further substantial process step, in particular any intervening or subsequent process steps. Thus, the present invention provides its advantages in a simple and cost-effective way.
- [0036] In a particularly preferred embodiment the cell culture system is a cell culture system, comprising a cell culture medium, preferably in a culture vessel, in particular a cell culture medium supplemented with at least one so called "inducing substance", which is a substance suitable and determined for protecting the cells from in vitro aging and/or inducing in an unspecific or specific reprogramming. In a particularly preferred embodiment an inducing substance
- ⁴⁵ according to the present invention is a substance selected from the group consisting of reversin, resveratol, selenium, a selenium-containing compound, EGCG ((-)-epigallocatechin-3-gallate), valporic acid and salts of valporic adic, in particular sodium valporat.

[0037] In a particularly preferred embodiment the at least one inducing substance is present in the cell culture medium used in step c) of the present process in a concentration from 0.001 to 100 μ M, preferably from 0.005 to 50 μ M.

- 50 [0038] In a particularly preferred embodiment the present invention foresees to use a concentration of reversin from 0.5 to 10 μM, preferably of 1 μM. In a furthermore preferred embodiment the present invention foresees to use resveratrol in a concentration of 10 to 100 μM, preferably 50 μM. In a furthermore preferred embodiment the present invention foresees to use selenium or a selenium containing compound in a concentration from 0.05 to 0.5 μM, preferably of 0.1 μM. In a furthermore preferred embodiment the present invention foresees to use selenium or a selenium containing compound in a concentration from 0.05 to 0.5 μM, preferably of 0.1 μM. In a furthermore preferred embodiment the present invention foresees to use EGCG in a concentration from 0.001
- to 0.1 μM, preferably of 0.01 μM. In a furthermore preferred embodiment the present invention foresees to use valpouric acid or sodium valporate in a concentration from 1 to 10 μM, in particular of 5 μM.
 [0039] The present invention foresees in a furthermore preferred embodiment culturing the cells obtained in step b) in a cell culture medium, wherein the cell culture medium comprises, optionally in combination with the inducing substance

as specified above, at least one transient proteolysis inhibitor. The use of at least one proteolysis inhibitor in the cell culture medium of the present invention increases the time the reprogramming proteins derived from the mRNA or any endogenous genes will be present in the cells and thus facilitates in an even more improved way the reprogramming by the transfected mRNA derived factors. The present invention uses in a particularly preferred embodiment as a transient

- ⁵ proteolysis inhibitor a protease inhibitor, a proteasome inhibitor and/or a lysosome inhibitor. In a particularly preferred embodiment the proteosome inhibitor is selected from the group consisting of MG132, TMC-95A, TS-341 and MG262. [0040] In a furthermore preferred embodiment the protease inhibitor is selected from the group consisting of aprotinin, G-64 and leupeptine-hemisulfat. In a furthermore preferred embodiment the present invention also foresees a cell culture medium comprising
- 10 at least one transient inhibitor of mRNA degradation. The use of a transient inhibitor of mRNA degradation increases the half-life of the reprogramming factors as well.

[0042] In a furthermore preferred embodiment of the present invention a condition suitable to allow translation of the transfected reprogramming mRNA molecules in the cells is an oxygen content in the cell culture medium from 0.5 to 21 %, preferably from 1 to 20%, more preferably from 5 to 19% and particularly preferred from 10 to 18%. More particular,

- ¹⁵ and without wishing to be bound to theory, oxygen is used to further induce or increase Oct4 by triggering Oct4 via Hif1a. [0043] In a preferred embodiment conditions that are suitable to support reprogramming of the cells by the mRNA molecules in the cells are selected; more particularly, these conditions require a temperature from 30 to 38°C, preferably from 31 to 37°C, most preferably from 32 to 36°C.
- [0044] The glucose content of the medium is in a preferred embodiment of the present invention below 4.6 g/l, preferably below 4.5 g/l, more preferably below 4 g/l, even more preferably below 3 g/l, particularly preferably below 2 g/l and most preferably it is 1 g/l. DMEM media containing 1 g/l glucose being preferred for the present invention are commercially available as "DMEM low glucose" from companies such as PAA, Omega Scientific, Perbio and Biosera. More particular, and without wishing to be bound to the theory, high glucose conditions adversely support aging of cells (methylation, epigenetics) in vitro which may render the reprogramming difficult.
- [0045] In a furthermore preferred embodiment of the present invention the cell culture medium contains glucose in a concentration from 0.1 g/l to 4.6 g/l, preferably from 0.5 g/l to 4,5 g/l and most preferably from 1 g/l to 4 g/l.
 [0046] The terms "cell culture" and "culturing of cells" refer to the maintenance and propagation of cells and preferably human, human-derived and animal cells in vitro.
- [0047] "Cell culture medium" is used for the maintenance of cells in culture in vitro. For some cell types, the medium may also be sufficient to support the proliferation of the cells in culture. A medium according to the present invention provides nutrients such as energy sources, amino acids and anorganic ions. Additionally, it may contain a dye like phenol red, sodium pyruvate, several vitamins, free fatty acids, antibiotics, anti-oxidants and trace elements.

[0048] For culturing the stem cells according to the present invention any standard medium such as Iscove's Modified Dulbecco's Media (IMDM), alpha-MEM, Dulbecco's Modified Eagle Media (DMEM), RPMI Media and McCoy's Medium is suitable before reprogramming. Ones the cells have been reprogrammed, they can in a preferred embodiment be

cultured in embryonic stem cell medium.
 [0049] Preferably, the medium additionally comprises one or more additives selected from the group consisting of

vitamin D3 (1,25-dihydroxyvitamin D3, cacitriol), resveratrol (trans-3, 4', 5-trihydroxystilbene), reversine (2-(4-mor-pholinoanilino)- N6-cyclohexyladenine), vitamin E (RRR- α -tocopherol), valproic acid (dekapene, valproate, valrelease),

⁴⁰ EGCG (epigallocatechin-3-gallat) and selenium. Preferably, two of the afore-mentioned additives are present, more preferably three of the afore-mentioned additives are present, even more preferably four of the afore-mentioned additives are present, particularly preferably five of the afore-mentioned additives are present and most preferably all of the aforementioned additives are present.

[0050] These media are well-known to a person skilled in the art and may be purchased from companies such as ⁴⁵ Cambrex, Invitrogen, Sigma-Aldrich or Stem Cell Technologies.

- [0051] The medium may in a particular embodiment further comprise a serum component such as horse serum, human serum or fetal calf serum (FCS). Preferably, the medium contains FCS. If present, the serum is present in a concentration of 1 -20%, preferably of 3-18%, more preferably of 5-15%, even more preferably of 8-12% and most preferably of 10%. Alternatively the serum component may be replaced by any of several standard serum replacement mixtures which typically include insulin, albumin and lecithin or cholesterol.
- [0052] A "culture vessel" is any vessel which is suitable for growing cells in a culture medium, in particular selected from, but not limited to, agar, matrigel and collagen, either in fluid phase or adhered to an interior surface of the container. Types of such specialized vessels include roller bottles, spinner flasks, petri dishes and tissue flasks. Culture vessels are designed to be incubated in temperature, humidity and gas controlled environments to facilitate maximum cell or
- ⁵⁵ tissue growth. Generally, a layer of cell culture medium or agar covers the growing surface. The portion of the vessel not utilized as a growing surface encloses the interior gaseous environment which surrounds the cell culture. Cells, tissues, microorganisms and the like typically are introduced into the interior of cell culture vessels through an opening in the vessel. After introduction of the cells the opening may be closed such that the cells are not in contact with the

environment during the culturing of the cells.

[0053] In a preferred embodiment of the present invention, the culture vessel is treated for tissue culture, which means that the surface of the culture vessel is treated such that cells which usually grow in an adherent state grow adherently, but cells which grow in suspension do not adhere or adhere only loosely. Such treatment may involve the irradiation of

- the vessel or the coating of the vessel, for example with a special plastic, polymer or nanostructure or with proteins of the extracellular matrix. Such vessels can comprise tissue culture dishes and tissue culture flasks and are available from different suppliers such as Becton Dickinson, Greiner, Sigma and TPP.
 [0054] The present invention also relates to a process for the production of cells exhibiting a multipotent, preferably
- a multipotent, stem cell character, wherein a process according to the above is carried out.
 [0055] The present invention also relates to a process for improving the expansion of stem cells in vitro, wherein a
- process according to the present invention is carried out. Thus, the present invention provides the advantage of prolonging expansion of stem cells, since the present invention keeps the cells to be expanded in a dedifferentiated status. **[0056]** The present invention also relates to a process for the rejuvenation of aged cells, wherein a process according to the present invention is carried out.
- ¹⁵ **[0057]** The present invention also relates to a process for inducing the dedifferentiation of cells, wherein a process according to the present invention is carried out and wherein in particular the cells to be reprogrammed are differentiated cells, in particular lineage-committed cells.

[0058] The present invention also relates to a process for reprogramming recipient cells of a mammal in vivo comprising introducing reprogramming mRNA molecules into the recipient cells of the mammal wherein the reprogramming mRNA

- 20 molecules are encoding at least one reprogramming protein selected from the group consisting of Ronin, Oct4, Klf4, Sox2, Nanog and TERT. Thus, the present invention also relates to an in vivo method for reprogramming recipient cells of a mammal which employ the reprogramming mRNA molecules as identified above for the in vitro embodiment of the present invention. The present invention relating to the process for reprogramming recipient cells of a mammal in vivo thereby foresees to introduce the reprogramming mRNA molecules directly into at least one cell of a recipient mammal
- that means into at least one recipient cell by suitable means such as gene gun insertion. Such a process allows the production of a mammal in particular a human being which has at least one reprogrammed cell. Thus, this embodiment of the present invention provides terrifically improved therapeutic application, in particular in the regenerative medicine and/or in replacement therapy. Thus, the present invention relates to a method of treating a mammal, in particular human being wherein reprogramming mRNA molecules are introduced into at least one cell of the recipient mammal and wherein
- the reprogrammed mRNA molecules are encoded at least by encoding at least one reprogramming protein selected from the group consisting of Ronin, Oct4, Klf4, Sox2, Nanog and TERT.
 [0059] The present invention also relates to a multipotent, in particular a pluripotent, stem cell prepared according to any one of the methods of the present invention. Thus, the reprogrammed cells according to the present invention are preferably multipotent, in particular pluripotent stem cells. In a preferred embodiment the cells obtained according to the
- ³⁵ present invention are distinguished from the cells used as a starting material in step a) of the present invention by lack of one or more markers. These cells may in a preferred embodiment be also characterized by a particular methylation pattern, by the expression of oct4, sox2, nanog, hTERT or klf4. expression of oct4, which is not found in somatic cells like fibroblasts, becomes expressed after transfecting mRNA (klf4, sox2 and oct4) in human fibroblasts, by improved growth potential; and by increased differentiation potential. For pluripotency the formation of embryoid bodies, production
- 40 of cells of all three germ layers in vitro and in vivo. Examples thereof are illustrated in the accompanying figures and example.

[0060] The reprogrammed cells obtained by the present processs may preferably be characterized by the expression or non-expression of certain surface markers. These surface markers are usually given a cluster of differentiation (CD) designation which describes groups of immunophenotypical surface characteristics of cells. Usually CD molecules are

- ⁴⁵ membrane-bound glycoproteins which are recognized by a cluster of monoclonal antibodies that display the same cellular reactivity. These surface molecules may for example be detected by means of a flow cytometer such as a fluorescenceactivated cell sorter (FACS) manufactured by companies such as Becton Dickinson. Methods to identify cells according to the present invention are methods to detect cell-specific proteins, methods to detect cell-specific transcription factors or methods to detect physiological or morphological changes. All of these methods are per se well-known in the prior
- ⁵⁰ art. In particular, these methods use well-known protein or DNA or RNA detection processes and/or the reporter gene assays. Of course, immunoassays or assays using fluorescently or radioactively labelled proteins or nucleic acids including methods to measure enzymatic activities can be employed. Methods to detect morphological changes may include staining methods, visually based methods or the like.
- [0061] Reprogrammed cells according to the present invention may be used for therapeutic, diagnostic or scientific purposes. In particular, these cells may be used in regenerative medicine and/or for replacement therapy.
 - [0062] The term "cell" not only refers to a single cell but also encompasses a cell line, a cell population or a cell clone.[0063] The term "stem cells" refers to cells which have retained the capacity to proliferate and differentiate into one or different cell types. Stem cells created in accordance with the present invention are preferably pluripotent stem cells,

i.e. stem cells which have retained the capacity to differentiate into distinct cell lineages and cell types or multipotent stem cells, retaining a more restricted differentiation potential.

[0064] It is understood that the term "stem cells" in accordance with the invention does not comprise human embryos.

Furthermore, it is understood that the term "stem cells" does not comprise pluripotent stem cells which have been directly derived from a human embryo. Embryonic stem cells which have been derived from publicly available and previously established stem cell lines are understood to fall within the meaning of the term "stem cells" as used by the present invention.

[0065] A "stem cell", as used herein, refers to any self-renewing pluripotent cell or multipotent cell or progenitor cell or precursor cell that is capable of differentiating into one or multiple cell types. Stem cells are thus cells able to differentiate

- ¹⁰ into one or more than one cell type and have preferably an unlimited growth potential. Stem cells include those that are capable of differentiating into cells of osteoblast lineage, a mesenchymal cell lineage (e. g. bone, cartilage, adipose, muscle, stroma, including hematopoietic supportive stroma, and tendon). "Differentiate" or "differentiation", as used herein, refers to the process by which precursor or progenitor cells (i. e., stem cells) differentiate into specific cell types, e. g., osteoblasts. Differentiated cells can be identified by their patterns of gene expression and cell surface protein
- 15 expression. "Dedifferentiate" or "dedifferentiation", as used herein, refers to the process by which lineage-committed cells (e. g., myoblasts or osteoblasts) reverse their lineage commitment and become precursor or progenitor cells (i. e., multipotent or pluripotent stem cells). Dedifferentiated cells can for instance be identified by loss of patterns of gene expression and cell surface protein expression associated with the lineage committed cells.
- [0066] A "lineage-committed cell" as used herein, refers to any cell that has or will differentiate into a particular cell type or related cell types. Lineage committed cells include, for example, osteoblasts, myoblasts, chrondrocytes, and adipocytes.

[0067] Totipotent stem cells are able to create all cell types of the body, including placental cells. The earlier stage foetal stem cells are considered totipotent, as well as the fertilised egg. They also have the ability to replicate in unlimited numbers without losing their potential.

²⁵ **[0068]** Pluripotent stem cells are able to create cells of all three germ layer, namely the ecto-, endo- and mesoderm. They also have the ability to replicate in unlimited numbers without losing their potential.

[0069] Multipotent stem cells are able to produce cells of one or more germ layers or several types of tissues. They often have an already limited self-renewal ability.

[0070] Stem cells are thus cells able to differentiate into one or more than one cell type and have preferably an unlimited growth potential.

[0071] Progenitor cells can differentiate into one or more cell types but have a limited growth potential.

[0072] Adult stem cells are stem cells derived from an adult organism and might be multipotent or pluripotent.

[0073] Embryonic stem cells are derived from the inner mass of a blastula and are pluripotent. Embryonic stem cells

are unique because they can develop into nearly all cell types, an attribute called pluripotency. But to access these cells, researchers must destroy a viable embryo. In this patent we are describing a way to create cells, with the characteristics

of embryonic stem cells, without the need to destroy embryos or the use of embryonic stem cells. [0074] Induced pluripotent stem cells "IPS" cells are pluripotent stem cells artificially derived from non-pluripotent cells, including somatic cells, adult multipotent stem cells or progenitor cells. In principal every cell containing a nuclei can be used as source for IPS cells.

- 40 **[0075]** Further preferred embodiments of the present invention are the subject matter of the subclaims.
- **[0076]** The sequence listing show the prior art DNA sequences encoding the mRNA nucleotide sequence molecules used in the present invention:

SEQ ID No.	gene	accession-number	length
1	hNanog	NM_024865	2098
2	mNanog	NM_028016	1356
3	rNanog	NM_001100781	2358
4	hSox2	NM_003106	2518
5	mSox2	NM_011443	2457
6	rSox2	NM_001109181	2323
7	hOct4	NM_002701	1411
8	mOct4	NM_013633	1346

Table 1

50

55

SEQ ID No.	gene	accession-number	length		
9	hKlf4	NM_004235	2949		
10	mKlf4	NM_010637	3057		
11	rKlf4	NM_053713	2393		
12	hTERT	NM_198253	4018		
13	mTert	ENSMUSG0000021611	4237		
14	rTERT	NM_053423	3378		
15	hRonin	NM_020457	1903		
16	mRonin	NM_021513	1832		
abbreviations: h = human; m = mouse; r = rat					

(continued)

5

10

15

20

25

40

45

[0077] The designations marked "NM" and ENSMUSG refer to the NM(NCBI)- and ENSMUSG-accession numbers as given under the publically available website http://www.ncib.nlm.nih.gov and http://www.ensembl.org.

[0078] SEQ ID No. 17 and 18 show the DNA sequence of primers used for cloning the human Nanog gene.

[0079] SEQ ID No. 19 and 20 show the DNA sequence of primers used for cloning the human Klf4 gene.

[0080] SEQ ID No. 21 and 22 show the DNA sequence of primers used for cloning the human Sox2 gene.

[0081] SEQ ID No. 23 and 24 show the DNA sequence of primers used for cloning the human Oct4 gene.

[0082] SEQ ID No. 25 and 26 show the DNA sequence of primers used for cloning the human Tert gene.

- [0083] SEQ ID No. 27 and 28 show the DNA sequence of primers used for cloning the GFP gene.
 - [0084] The present invention will now be illustrated in more detail by way of an example and figures.
 - [0085] The figures show:
- Figure 1: Promotor methylation of rex1, nanog and oct4 in human fibroblasts before and after reprogramming (Figure
 ³⁰ 1A: Rex; Figure 1AB: Nanog; Figure 1C: Oct4). CpG island are represented as squares. Black squares represent methylated and white squares represent unmethylated CpG islands. All samples are primary fibroblasts from a young male donor.
- $\frac{\text{Figure 2:}}{35}$ Fluorescence and morphology after amaxa elektroporation (klf4, sox2, oct4): Human primary fibroblasts were transfected with 0,6 µg/µl mRNA per factor and 0,2 µg/µl GFP mRNA to visualize the transfection effciency. Top line are fluorescence pictures and the bottom line shows the morphology of the cells after 2 days.

Figure 3: Fluorescence and morphology after Fugene transfection (klf4, sox2, oct4): Human primary fibroblasts were transfected with 0,6 μg/μl mRNA per factor and 0,2 μg/μl GFP mRNA to visualize the transfection effciency. Top line are fluorescence pictures and the bottom line shows the morphology of the cells after 7 days.

Figure 4: RT-PCR for Oct4: L: 20 bp Ladder (Fermentas); 1 hOct4 hypoxy factors1x transfected; 2: hOct4 hypoxy factors 6x transfected; 3: hOct4 hypoxy factors 6x transfected +Cock; 4: hOct4 normoxy factors 1x transfected; 5: hOct4 normoxy factors 6x transfected; 6: hOct4 normoxy factors 6x transfected +Cock; 7: hOct4 normoxy factors 6x transfected +Cock+MG-132; 1 a: hOct4 RNA after DNase digestion; 2a: hOct4 RNA after DNase digestion; 3 a: hOct4 RNA after DNase digestion; 4a: hOct4 RNA after DNase digestion; 5a: hOct4 RNA after DNase digestion; 6a: hOct4 RNA after DNase digestion; 7a: hOct4 RNA after DNase digestion; 8: Oct4 negative control.

Figure 5: RT-PCR for hOct4: L: 20 bp Ladder (Fermentas); 1 : hOct4 hypoxy factorslx transfected (human fibroblasts);
 ⁵⁰ 2: hOct4 hypoxy factors 6x transfected (human fibroblasts mit mRNA transfected); 3: hOct4 hypoxy factors 6x transfected +Cocktail (human fibroblasts transfected with mRNA and chemical reprogramming cocktail); 4: hOct normoxy factors 1x transfected; 5: hOct4 normoxy factors 6x transfected; 6: hOct4 normoxy factors 6x transfected + cocktail, 7: hOct4 normoxy 6x transfected factors + cocktail + MG-132; 8: hOct4 positive control (plasmid with hKlf4), 9: hOct4 negative control (water).

55

Figure 6: RT-PCR for hOct4 and GAPDH: 1 hOct4 hypoxy factorslx transfected; 2 hOct4 hypoxy factors 6x transfected; 3 hOct4 hypoxy factors 6x transfected +chemical cocktail; 4 hOct4 normoxy factors 1x transfected; 5 hOct4

normoxy factors 6x transfected; 6 hOct4 normoxy factors 6x transfected + chemical cocktail; 7 hOct4 normoxy factors 6x transfected + chemical cocktail + MG-132; 1 a hOct4 RNA after DNase digestion; 2a hOct4 RNA after DNase digestion; 3a hOct4 RNA after DNase digestion; 4a hOct4 RNA after DNase digestion; 5a hOct4 RNA after DNase digestion; 6a hOct4 RNA after DNase digestion; 7a hOct4 RNA after DNase digestion; 8a Oct4 RNA after DNase digestion; 1 b GAPDH hypoxy factors 1x transfected; 2b GAPDH hypoxy factors 6x transfected; 3b GAPDH hypoxy factors 6x transfected; 5b GAPDH hypoxy factors 6x transfected; 6b GAPDH normoxy factors 6x transfected + chemical cocktail; 4b GAPDH negative control.

Figure 7: RT-PCR for hKlf4 and hNanog: L: 20 bp Ladder (Fermentas); 1a: hKlf4 hypoxy factors1x transfected (human fibroblasts); 2a: hKlf4 hypoxy factors 6x transfected (human fibroblasts with transfected mRNA); 3 a: hKlf4 hypoxy factors 6x transfected + cocktail (human fibroblasts transfected with mRNA + chemical reprogramming cocktail); 4a: hKlf4 normoxy factors 1x transfected; 5a: hKlf4 normoxy factors 6x transfected; 6a: hKlf4 normoxy factors 6x transfected + cocktail, 7a: hKlf4 normoxy 6x transfected factors + cocktail + MG-132; 8a: hKlf4 pos. control (plasmid with hKlf4), 9a: hKlf4 neg. control (water) 1b: hNanog hypoxy factors1x transfected (human fibroblasts); 2b: hNanog hypoxy factors 6x transfected (human fibroblasts transfected with mRNA transfected); 3b: hNanog hypoxy factors 6x transfected; 5b: hNanog normoxy factors 6x transfected; 6b: hNanog normoxy factors 6x transfected; 5b: hNanog normoxy factors 6x transfected; 6b: hNanog normoxy factors 6x transfected; 5b: hNanog normoxy 6x transfected; 6b: hNanog normoxy factors 6x transfected; 5b: hNanog normoxy 6x transfected; 6b: hNanog normoxy factors 6x transfected; 5b: hNanog normoxy 6x transfected; 6b: hNanog normoxy factors 6x transfected; 5b: hNanog normoxy 6x transfected; 6b: hNanog normoxy factors 6x transfected; 5b: hNanog normoxy 6x transfected; 6b: hNanog normoxy factors 6x transfected; 20

Figure 8: Results from RNA BioAnalyzer Analysis (Agilent Nano Chip; Agilent Technologies) for oct4, sox2, and klf4:

[0086] Further preferred embodiments of the invention are reflected by the below consecutively numbered sentences:

1. A process for preparing reprogrammed cells in vitro, comprising

a) providing cells to be reprogrammed,

b) introducing reprogramming mRNA molecules into the cells provided in step a), wherein the reprogramming mRNA molecules are encoding at least one reprogramming protein selected from the group consisting of Ronin, Oct4, Klf4, Sox2, Nanog and TERT,

c) culturing the cells obtained in step b) in a cell culture medium and under a condition suitable to allow translation of the transfected reprogramming mRNA molecules so as to obtain reprogrammed cells.

2. The process according to embodiment 1, wherein the condition suitable to allow translation is an oxygen content in the cell culture medium from 0.5 % to 21 %.

3. The process according to embodiments 1 or 2, wherein the condition suitable to allow translation is a temperature from 30°C to 38°C.

40

25

30

5

4. The process according to any one of the preceding embodiments, wherein the cell culture medium has a glucose content of 0.1 g/l to 4.6 g/l.

5. The process according to any one of the preceding embodiments, wherein the cell culture medium contains at least one inducing substance selected from the group consisting of reversin, resveratol, selenium, selenium containing compounds, EGCG ((-)-epigallocatechin-3-gallate), valporic acid, salts of valporic acid and sodium valproate.

6. The process according to any one of embodiments 1 to 5, wherein the cell culture medium contains at least one transient proteolysis inhibitor.

50

45

7. The process according to embodiment 6, wherein the transient proteolysis inhibitor is selected from the group consisting of protease inhibitor, proteasome inhibitor and lysosome inhibitor.

8. The process according to any one of the preceding embodiments, wherein the cells to be reprogrammed are human cells.

9. The process according to any one of the preceding embodiments, wherein the cells to be reprogrammed are nonembryonic stem cells.

10. A process for the production of cells exhibiting a pluripotent or multipotent stem cell character, wherein a process according to any one of embodiments 1 to 9 is carried out.

11. A process for inducing the dedifferentiation of cells, wherein a process according to any one of embodiments 1 to 9 is carried out.

12. A process for improving the expansion of non-embryonic stem cells in vitro, wherein a process according to any one of embodiments 1 to 9 is carried out.

¹⁰ 13. A process for the rejuvenation of aged cells, wherein a process according to any one of embodiments 1 to 9 is carried out.

14. A multipotent or pluripotent stem cell prepared according to any one of the methods of embodiments 1 to 10.

15 15. A process for reprogramming recipient cells of a mammal in vivo comprising introducing reprogramming mRNA molecules into the recipient cells of the mammal wherein the reprogramming mRNA molecules are encoding at least one reprogramming protein selected form the group consisting of Ronin, Oct4, Klf4, Sox2, Nanog and TERT.

<u>Example</u>

20

5

1. Preparation of reprogramming mRNA

1. A) Preparation of mRNA expression plasmids

²⁵ [0087] For the construction of plasmids comprising the target genes in a vector with the T7-promoter for in *vitro* transcription, using PCR, digest sites before the start-codon and after the stop codon were designed for direct cloning of the gene inserts (see Table 1) in the right direction into the pCR@II-Vector (Invitrogen). [0088] The primers used are listed in Table 2.

30		Table 2		
	Name gen	New digest sites for restriction enzymes	Primer sequence 5'-3'	Product size
	Nanog_human	Xbal & Notl	SEQ ID No. 17	918 bp
35	Nanog_human	Spel & Clal	SEQ ID No. 18	910 pp
35	Klf4_human	Xbal & Notl	SEQ ID No. 19	637 bp
	Klf4_human	HindIII & Clal	SEQ ID No. 20	037 bp
	Sox2_human	Xbal & BamHI	SEQ ID No. 21	996 bp
40	Sox2_human	HindIII & Clal	SEQ ID No. 22	990 pp
	Oct4_human	Xbal & Notl	SEQ ID No. 23	1100 bp
	Oct4_human	BamHI & Clal	SEQ ID No. 24	1100 bp
45	Tert_human	Xbal & Notl	SEQ ID No. 25	783 bp
	Tert_human	HindIII & Clal	SEQ ID No. 26	705 bp
	GFP	Xbal & Notl	SEQ ID No. 27	724 bp
	GFP	HindIII & Clal	SEQ ID No. 28	127 VP

50

[0089] A PCR for obtaining the desired digest sites was carried out with the Platinum Taq-Polymerase (Invitrogen).

Preparation of PCR-reaction on ice:

⁵⁵ [0090]

5 μl 10x PCR Buffer

(continued)

			(continued)	
5	1 1 1 0	μΙ .5 μΙ μΙ μΙ).2 μΙ ο 50 μΙ	10 mM dNTP mixture 0.2 mM each 50 mM MgCl2 Primer mix (10 μM each) 0.2 μM eac Template DNA Platinum [®] Taq DNA Polymerase 1.0 μ DEPC-H ₂ O	
10	PCR-Program (Biometra Tprofessio	onal):		
	[0091]			
15	95°C		2 min	
	95°C		30 sec	←
	60°C		30 sec	35 x
20	70°C		30 sec	
	70°C		10 min	
25	4°C		for ever	

[0092] After electrophoresis in a 1 % TAE-agarose-gel, specific DNA-bands (for their size see Table 2) were cut out and the DNA extracted and purified with the QIAquick Gel Extraction Kit (from Qiagen)

30 Procedure:

[0093]

35

45

55

- excise the DNA fragment from the agarose gel with a scalpel
- weigh the gel slice
- add 3 volumes of Buffer QG to 1 volume of gel (For example, add 300 μl of Buffer QG to each 100 mg of gel)
- incubate at 50°C for 10 min (or until the gel slice has completely dissolved)
- add 1 gel volume of isopropanol to the sample and mix
- place a QIAquick spin column in a provided 2 ml collection tube
- to bind DNA, apply the sample to the QIAquick column, and centrifuge for 1 min at 13,000 rpm
- 40
 discard flow-through
 - add 0.5 ml of Buffer QG to QIAquick column and centrifuge for 1 min at 13,000 rpm
 - to wash, add 0.75 ml of Buffer PE to QIAquick column and centrifuge for 1 min at 13,000 rpm
 - discard the flow-through
 - centrifuge the QIAquick column for an additional 1 min at 13,000 rpm
 - place QIAquick column into a 1.5 ml micro centrifuge tube
 - to elute DNA, add 50 μl of H20 to the centre of the QIAquick membrane, let the column stand for 1 min, and then centrifuge for 1 min at 13,000 rpm
- [0094] Digest of pCRII-Vector with the specific restriction enzymes for cloning of target-DNA

Strategy for digest of vector pCRII:

[0095]

vector pCRII digest with Xbal and SpeI for target gene human Nanog vector pCRII digest with XbaI and HindIII for target gene human Klf4 vector pCRII digest with XbaI and BamHI for target gene human Sox2

vector pCRII digest with Xbal and BamHI for target gene human Oct4 vector pCRII digest with Xbal and HindIII for target gene human TERT vector pCRII digest with Xbal and HindIII for target gene GFP

⁵ <u>Preparation of digest on ice:</u>

[0096]

- 5 μl 10x Buffer
- 10 ≥2 μg plasmid
 - $2 \mu I$ restriction enzyme
 - to 50 μl DEPC-water
 - incubation for 1 h at 37°C (thermo block; Eppendorf)
 - heat inactivation for 20 min by the specific temperature of the enzyme

[0097] Ligation of the target-gene inserts DNA with the linear vector DNA with the T4-DNA-Ligase (Fermentas)

Preparation of the ligation on ice:

20 [0098]

15

- 50-400 ng vector DNA
- 50-400 ng insert DNA
- ²⁵ 2 μl 10x Buffer
 - 0.2 μl (1U) T4-DNA Ligase
 - to 20 µl DEPC-water
 - vortex the tube and spin down in a micro centrifuge for 3-5 seconds
 - incubate on room temperature for 1 h
 - heat inactivation for 20 min
 - 1. B) Transformation of the plasmids with chemical competent DH5 α -bacteria

35 **[0099]**

30

- add 1 μ l of the plasmids to 10 μ l chemical competent DH5 α -bacteria
- incubation for 30 min on ice
- heat shock at 42°C for 45 sec
- add 250 μl SOC-Medium to the bacteria
 - incubation at 37°C for 1h with shaking
 - plate out the bacteria solution on LB-kanamycin-agarose-plate and incubate the plate for 12 hours in 37°C incubator
 - pick one colony of the bacteria and put the colony in 5 ml LB-medium and incubate the solution for 12 hours in a bacteria incubator with shaking
- 45

55

1. C) Plasmid DNA purification with the NucleoSpin® Plasmid -KIT (Machery&Nagel)

[0100]

- 50 5 ml of a saturated E. coli LB culture, pellet cells in a standard bench top micro centrifuge for 30 sec at 11,000 x g.
 discard the supernatant
 - for cell lysis add 250 μl Buffer A1. Re-suspend the cell pellet completely by pipetting up and down
 - add 250 μl Buffer A2
 - mix gently by inverting the tube 10 times and Incubate at room temperature for up to 5 min
 - add 300 μl Buffer A3. Mix thoroughly by inverting the tube 10 times
 - centrifuge for 5 min at 11,000 x g at room temperature
 - place a NucleoSpin® Plasmid Column in a collection tube (2 ml) and load a 750 µl of the supernatant onto the column.
 - centrifuge for 1 min at 11,000 x g.

- discard flow-through and place the NucleoSpin® Plasmid Column back into the collection tube (2 ml)
- for wash the membrane with DNA: Add 600 μ l Buffer A4 (supplemented with ethanol).
- centrifuge for 1 min at 11,000 x g.
- discard flow-through and place the NucleoSpin® Plasmid Column back into the collection tube (2 ml)
- dry silica membrane: centrifuge for 2 min at 1 1,000 x g and discard the collection tube (2 ml)
- elute DNA: place the NucleoSpin® Plasmid Column in a 1.5 ml micro centrifuge tube and add 50 μl H20 and incubate for 1 min at room temperature.
- centrifuge for 1 min at 11,000 x g
- measure the DNA-concentration with the nanodrop
- ¹⁰ DNA store at -20°C

1. D) Linearisation of the pCRII-hoct4, pCRII-hSox2, pCRII-hKIf4 plasmids for the in vitro transcription

[0101]

5

- pCRII-hoct4 digest with BamHI
- pCRII-hSox2 digest with HindIII
- pCRII-hKlf4 digest with HindIII
- 20 Preparation of digest on ice:

[0102]

- 5 μl 10x Buffer
- ²⁵ 2 μg Plasmid
 - 2 µl Restriction-Enzyme
 - to 50 μl DEPC-H₂0
 - incubation for 1 h at 37°C (thermo block; Eppendorf)
 - heat inactivation for 20 min by the specific temperature of the enzyme
 - heat inactivate both enzyme for 20 min at 80°C

1. E) Purification of the linearized pCRII-hoct4, pCRII-hSox2, pCRII-hKlf4 plasmids with QIAquick PCR Purification Kit (from Qiagen)

[0103]

30

35

45

- add 5 volumes of Buffer PB to 1 volume of the digest sample and mix
- place a QIAquick spin column in a provided 2 ml collection tube
- 40 to bind DNA, apply the sample to the QIAquick column and centrifuge for 60 s
 - discard flow-through
 - place the QIAquick column back into the same tube
 - to wash, add 0.75 ml Buffer PE to the QIAquick column and centrifuge for 60 s
 - discard flow-through and place the QIAquick column back in the same tube
 - to dry the membrane, centrifuge the column for an additional 1 min
 - place QIAquick column in a 1.5 ml micro centrifuge tube
 - to elute DNA, add 10 μ l H20 to the centre of the QIAquick membrane, let the column stand for 1 min, and centrifuge the column for 1 min
 - measure the DNA-concentration with the nanodrop
- 50 store DNA at -20°C

1. F) in vitro transcription of the linearized pCRII-hoct4, pCRII-hSox2, pCRII-hKlf4 plasmids with mMessage mMachine high yield capped RNA Transcription Kit (from Ambion) and add a poly(A) tail to RNA transcripts (Poly(A)-Tailing Kit from Ambion)

55

Preparation of the in vitro transcription (mMESSAGE mMACHINE reaction):

[0104]

- to 20 μl nuclease-free water
- 10 μl 2x NTP/CAP
- 2 μl 10x reaction buffer
- 1 μg linear template plasmid
- ⁵ $2 \mu l$ enzyme mix
 - pipette the mixture up and down gently
 - short centrifugation to collect the reaction mixture at the bottom of the tube
 - incubation for 2 h at 37°C
- 10 add 1 μl TURBO DNase to the mRNA and mix well
 - incubate at 37°C for 15 min
 - direct after the DNase-treated reaction add the poly(A)-tail to the mRNA
 - Preparation for poly(A)-tail reaction:
- 15

20

30

35

45

55

[0105]

- 20 µl mMESSAGE mMACHINE reaction
- 36 μl nuclease-free water
- 20 µl 5x E-PAP Buffer
- 10 μl 25 mM MnCl2
- 10 μl mM ATP
- 4 μl E-PAP
- ²⁵ mix gently
 - incubate at 37°C for 1 h
 - place reaction on ice
 - lithium chloride precipitation of the mRNA with poly(A)-tail:
 - add 30 µl LiCl Preciptitation Solution
 - mix thoroughly
 - chill for 30 min at -20°C
 - centrifuge at 4°C for 15 min at maximum speed to pellet the RNA
 - remove the supernatant
 - wash the pellet once with 1 ml 70% ethanol
 - centrifuge at 4°C for 15 min at maximum speed to pellet the RNA
 - remove the 70% ethanol
 - air-dry the pellet
 - solve the RNA-Pellet with 30-50 ml nuclease-free-water
 - the concentration of the RNA is measured with the nanodrop
- 40 the quality of the RNA is measured with the Agilent nano-chip
 - 2. Preparation of target cells
 - 2. A) Preparation of mouse and rat MSCs

[0106]

- kill the rat or mouse with CO2-gassing
- spray the rats and mice with 70% Ethanol to kill of bacteria and fungal spores
- 50 remove the coat from the skin
 - remove the back legs cleanly at the hip joint
 - under sterile conditions, remove all soft tissue and separate the bones
 - remove the growth plates both femur and tibia
 - insert holes with a needle into the bones on both ends
 - place the bones in eppendorf tubes (for mice) or in falkon tubes (for rats) and spin at 2000 rpm for 1 min (all of the bone marrow will be deposited in the bottom of the tube sitting in spacers); remove the bones and spacer
 - re-suspend the marrow in 0,5 ml medium (DMEM low glucose; 10 % FCS; 1 % Pen/Strep)
 - disseminate the marrow of one leg from a rat in 1 T-75 flask with 12 ml medium

- disseminate the marrow of two legs from a mouse in 1 10 cm petri-dish with 12 ml medium
- 2. B) Preparation of human MSC

5 [0107]

- get a bone marrow aspirate
- re-suspend in DMEM (low glucose, 10%FCS)
- plate out in a tissue culture flask
- growth for 5 days and then change media
 - thereafter change the medium twice weekly
 - culture in tissue culture flask until 80% confluency and subcul ture until needed
 - 2. C) Preparation of mouse and rat fibroblasts
- 15

20

35

40

45

10

[0108]

- cut of the tail
- shave the tail with a scalpel
- spray the tail with 70% ethanol to kill of bacteria and fungal spores
- remove the skin from the tail
- place the skin in a 10 cm petri dish
- under sterile conditions, cut the skin in small pieces (5 x 5 mm)
- digest the skin-pieces with 0,05 % Trypsin EDTA for 20 min in 37°C CO2-Incubator
- wash the trypsin from the skin-dishes with medium (DMEM high glucose, 10 % FCS, 1 % Pen/Strep), remove the medium and wash again for 3-4 times
 - then incubate the skin pieces in 37°C CO2-Incubator and change the medium every day, after 1 week the fibroblasts growth out
- 30 2. D) Preparation of human fibroblasts

[0109]

- place prepuce in petri dish
- wash two times with PBS
- remove fat
- wash with PBS one time
- cut the skin in small pieces (2 mm)
- add 10ml) dispase (2 U/ml)
- incubate at 4°C for 16-18 h
- discard dispase solution
- add 5 ml PBS
- seperate dermis and epidermis
- transfer dermis to new dish and add 10ml collagenease (500 U/ml)
- make very small pieces
- transfer pieces into a 50 ml falcon tube with solution and incubate for 45 min (37°C; 5% CO2)
- centrifuge at 1000rpm for 5 min
- discard supernatant and resuspend pellet in DMEM (10% FCS)
- centrifuge again
- 50 reuspend pellet in 2 ml DMEM (10% FCS) and transfer into a T75 cell culture flacon
 - expanded cells until use

3. mRNA Transfection

3. A) mRNA-transfection of human fibroblasts, human MSC, rat fibroblasts, rat MSC, mouse fibroblasts and mouse MSC with AMAXA, FugeneHD, Lipofectamine[™] LTX Reagent and PLUS[™] Reagent

5

15

1) AMAXA-Transfection with the Human Dermal Fibroblast Nucleofector® Kit (6 well-plate):

Preparation for one electroporation in certified Amaxa cuvette:

10 **[0110]**

- mRNA of oct4, sox2 and klf4 in sum of 2 μ g
- 4x105 cells
- 100 μl Nucleofector® Solution
- choose the program U-023 by the Amaxa-electroporation-machine
- re-suspend the cells in the cuvette with 500 μl fibroblast or MSC-Medium
- provide 5 ml fibroblast or MSC-Medium with or without Cocktail in every well of a 6 well-plate
- plate out 100.000 cells in each well of a 6 well-plate

20 Cocktail composition:

[0111]

- Resveratrol 0,05 mM
- ²⁵ Selenium 0,1 μM
 - EGCG ((-)-Epigallocatechin gallate) 0,01 μM
 - TSA (Trichostatin A) 0,015 μM
 - Reversin 1 μM
 - VPA (2-Propylpentanoic acid free acid) 6 μM
 - 5'Aza (5-Aza-2'-deoxycytidine) 1 μM
 - at day 1: the cocktail is with 5'Aza and without TSA; after 48 hours 5'Aza replaced by TSA
 - every 72 hours new transfection with FuGENE® HD Transfection Reagent (Roche)
- 35

30

2) Transfection FuGENE® HD Transfection Reagent (Roche)

[0112] >

40 - before transfection: change to antibiotic free medium

Transfection procedure

[0113]

45

- Dilute mRNA with serum-free and antibiotic-free medium to a concentration of 2 μ g mRNA at a volume of 100 μ l for each well (6well-plate)
- Pipet the 8 μl FuGENE® HD Transfection Reagent (Ratio: 8:2 Transfection reagent to mRNA) directly into the medium pipette up and down
- Incubate the transfection reagent: mRNA complex for 15 minutes at room temperature
 - Add the transfection complex to the cells in a drop-wise manner
 - Swirl the wells to ensure distribution over the entire plate surface
 - after 4-6 hours change to medium (contains 10 % FCS, 1 % Pen/Strep) with or without cocktail
- one transfected 6 well plate incubate at 21 % O2-condition (normoxy) and a second plate incubate at 1 % 02-
- ⁵⁵ condition (hypoxy) at 37°C incubator

- 3) Alternative transfection with Lipofectamine™ LTX Reagent or PLUS™ Reagent (Invitrogen)
- a) Transfection FuGENE® HD Transfection Reagent (Roche)

⁵ [0114]

10

15

20

30

- plate out 7000 cells in 500 μ l medium per well of a 24 well-plate
- incubate over night
- for transfection: change to antibiotic free medium
- lute 0,5 μg mRNA in 25 μl serum-free and antibiotic-free medium for each well (24well-plate)
- pipette the FuGENE® HD Transfection Reagent 2 μl (Ratio: 8:2 Transfection reagent to mRNA) directly into the medium
 - pipette up and down
- incubate the transfection reagent: mRNA complex for 15 minutes at room temperature
 - add the transfection complex to the cells in a drop-wise manner
 - swirl the wells to ensure distribution over the entire plate surface
 - after 4-6 hours change to medium (contains 10 % FCS, 1 % Pen/Strep) with or without cocktail
 - b) Lipofectamine[™] LTX Reagent and PLUS[™] Reagent (Invitrogen)

[0115]

- plate out 7000 cells in 500 µl Medium per well of a 24 well-plate
- incubation over night
- ²⁵ before transfection: change to antibiotic free medium
 - dilute 0,5 μg mRNA in 100 μl serum-free and antibiotic-free medium for each well (24well-plate)
 - mix gently
 - mix PLUS Reagent gently before use
 - add 0,5 μl PLUS[™] Reagent in the mRNA-Medium mix, mix gently and incubate 5 min at room temperature mix Lipofectamine[™] LTX Reagent gently before use
 - add 1,25 μl directly to the diluted mRNA); mix gently
 - incubate for 30 min at room temperature
 - add the 100 μl mRNA- Lipofectamine $^{\rm TM}$ LTX Reagent complex
 - to the well
- ³⁵ mix gently by rocking the plate back and forth
 - incubate the cells at 37°C in the CO2 incubator for 4-6 hours
 - change to medium with or without cocktail
 - during the optimization of the transfection efficiency \rightarrow in crease of the amount of mRNA concentration at 1 µg per well (24 well plate)
- 40 every 72 h repeat the transfection with FuGENE® HD or Lipofectamine™ LTX Reagent and PLUS™ Reagent
 - 4. Protease inhibitor treatment (MG132) to increase the half-life of the proteins produced by the transfected mRNA:

[**0116**]

 48h after transfection: treatment of two wells in every plate with MG-132 (10 μM/well) with and without cocktail for 6 h, than change medium

5. Results

50

[0117] Analysis of mRNA amount (per PCR) of the transfected or internal genes (oct4, nanog, hTERT, sox2, klf4) and promoter analysation (of nanog, sox, oct4)

[0118] The reprogramming results are set forht in figures 1 to 8

6. Tools and Methods

6.1 RNA-Isolation with TriFaSt™(Peglab)

⁵ [0119]

- 1 ml Trifast per 10 cm² of the culture dish area
- samples can be stored for a long time at -80°C or be directly used
- samples should be kept for 5 minutes at room temperature
- ¹⁰ addition of 0.2 ml of chloroform
 - shake samples by hand vigorously for 15 seconds
 - incubation for 3 minutes at room temperature
 - centrifugation at 12.000 x g
 - transfer the aqueous phase with RNA to new tube (save the interphase and organic phase at 4°C for the isolation of DNA and proteins).
 - precipitation of the RNA with 0.5 ml of Isopropanol per 1 ml of Tri-Fast™ used for the initial homogenization.
 - incubation on ice for 15 min
 - centrifuge for 10 minutes at 4°C at 12.000 g
 - remove the supernatant
 - wash the RNA pellet twice with 75% ethanol by vortexing
 - subsequent centrifugation for 8 minutes at 7,500 x g (4°C)
 - remove the excess isopropanol from the RNA pellet by airdrying
 - re-suspend the RNA pellet in Rnase-free water (DEPC-H20) \rightarrow 30 μl 50 μl
 - dissolve the RNA pellet by passing the solution through a pipette tip several times
- incubating the solution for 10 min at 55°C
 - pipetting it up and down.
 - Heating the sample at 55-60°C might help to dissolve the pellet
 - measure the RNA-Concentration \rightarrow NanoDrop
 - samples store at -80°C for 2-3 months

30

40

45

15

20

6.2 DNA-Isolation:

[0120]

- ³⁵ Remove any left aqueous phase after RNA removal
 - precipitate the DNA with 0.3 ml of 100% ethanol per ml Tri-Fast™
 - mix well by inversion
 - store the samples at room temperature for 2-3- minutes
 - centrifugation at 2,000 x g at 4°C for 5 minutes
 - move the DNA supernatant (store it at 4°C for the protein isolation)
 - DNA pellet washed twice with 1 ml 0.1 M sodium citrate in 10% ethanol
 - At each wash step keep the DNA in 0.1 M sodium citrate /10% ethanol for 30 minutes at room temperature (with periodic mixing)
 - centrifuge at 4°C for 5 minutes at 2,000 x g
 - after these two washes suspend the DNA pellet in 2 ml of 75% ethanol
 - keep it at room temperature with periodic mixing for 15 minutes
 - centrifuge at 2,000 x g for 5 minutes at 4°C
 - dry the DNA pellet briefly for 5-10 minutes under vacuum and
 - dissolve it in 8 mM NaOH by slowly passing the pellet through a wide bore pipet.
- 50 Try to adjust the final concentration of DNA to 0.2-0.3 μ g/ μ l with 8 mM NaOH

6.3 RNA treatment with DNase I (Fermentas):

[0121]

- 55
- 1 μg RNA
- 1 μl 10X reaction buffer with MgCl2
- 1 μl (1 u) DNase

- to 9 μl DEPC-H2O
- incubate at 37°C for 30 minutes
- inactivation of DNase I: Add 1 μ l 25mM EDTA and incubate at 65°C for 10 min

5

15

30

6.4 RT-PCR with SuperScript[™] III Reverse Transcriptase (Invitrogen)

Reaction condition:

10 **[0122]**

- 1 μl oligo(dT)20 Primer
- 1 μg RNA
- 1 μl 10 mM dNTP Mix (10 mM each dATP, dGTP. dCTP and dTTP)
- to 13 μl DEPC-H20
- heat mixture to 65°C for 5 minutes
- incubate on ice for 1 min

20 Add:

[0123]

- 4 μl 5X First-Strand Buffer
- ²⁵ 1 μl 0.1M DTT
 - 1 μl SuperScript™ III RT (200 units/μl)
 - mix by pipetting gently up and down
 - incubate at 50°C for 60 min
 - inactivate the reaction by heating at 70°C for 15 minutes
 - store the cDNA at -20°C

6.5 PCR of human oct4 (control the human fibroblasts):

³⁵ [0124] Primersequence: hoct4_S: gaggatcaccctgggatatacahoct4_as: agatggtcgtttggctgaatac
 [0125] Product size: 100 bp

6.6 PCR with Patinum Taq-Poymerase (Invitrogen)

40 Preparation of PCR-reaction on ice:

[0126]

- 5 μl 10X PCR Buffer
 - 1 µl 10 mM dNTP mixture 0.2 mM each
 - 1.5 μl 50 mM MgCl2
 - 1 μl Primer mix (10 μM each) 0.2 μM each
 - 1 μl Template DNA
 - 0,2 μl Platinum® Taq DNA Polymerase 1.0 unit
- to 50 μl DEPC-H20

PCR-Program (Biometra Tprofessional):

[0127]

55

45

	95°C	2 min
	95°C	30 sec
5	60°C	30 sec 35 x
	70°C	30 sec
10	70°C	10 min
10	4°C	for storage

PCR-control with 3% TAE-agarose-gel for electrophoresis

15 6.7 Protocol to produce iPScells

6.7.1 BD Matrigel™ hESC-qualified Matrix

[0128]

- 20
 - put the sterilized tip box and eppendorf tubes over night in 20°C freezer
 - thaw the Matrigel bottle on ice in the 4°C fridge overnight
 - aliquot Matrigel for hESC upon arrival, store at -80°C, only thaw once and do not re-freeze to avoid breakdown of growth factors
- ²⁵ for coating purposes, dilute Matrigel appropriately by using serum-free medium (0.3 μ g/ μ l for iPS, 1 μ g/ μ l for hESC)
 - add 50 µl Matrigel-dilution per cm2 growth surface
 - incubate 60 min at RT under sterile conditions or overnight at 4°C
 - soak off remaining Matrigel/medium
 - Medium: mTeSRI (Stem Cell Technology)
- 30

[0129] Notes: Coating recommendations (0.3 μ g/ μ l) is of course dependant on the cell type that you are using to generate iPS. It is recommended to coat (not gel!) plastics for hESC culture using 1 ug Matrigel/ μ l. Use plates immediately or store for max 7 days at 4°C covered with serum-free medium under aseptical conditions (sealed).

[0130] Please note that you always should process, store and use your coated Matrigel plates exactly the same way to avoid variabilities (mainly through breakdown of growth factors). In the beginning or for establishment it nessesary to titrate a coating volume and - concentration (maybe 3 dilutions 0.3, 0.6, 1 ug/ul) that suit your specific type of cells best.

6.7.2 BD Matrigel[™] Basement Membrane Matrix, Growth Factor Reduced (GFR)

40 [0131]

45

50

- aliquote the matrigel such as hESC-qualified Matrigel
- thaw tube overnight on ice at 4°C
- dilute with 6 ml cold basal media and mix well
- add 1 ml per well of 6 well plate
 - incubate the plate at room temperature for one hour or overnight at 4°C
 - plate may either be used immediately or stored at 4°C (plate are be good for least one week)
- remove the excess liquid and wash once with basal medium
- basal medium component: D-MEM/F-12; 20% KO Serum Replacer; 1% Non-essential Amino Acids; 1mM L-Glutamine, 0.1 mM 2-Mercaptoethanol; 100 ng/ml bFGF
 - use mouse cells then add LIF-supernatent to the basal medium
- 6.7.3 Production of LIF-supernatant

⁵⁵ [0132]

- coat petri dish (145 mm) with 0,1 % gelantine (Bovine Type x?, Sigma)
- plate 3x10e10 LIF producing feeder cells SNL in every dish

- Medium component: D-MEM high glucose, 10% FCS, 1 % Pen/Strep; 1 % L-Glutamine
- after 24 hours collect the medium from the dish and filter through a 0,22 μm filter
- aliquote the medium containing LIF in 500 μI aliquots and store at -20°C
- change media after 24 hours or 48 hours

10			
15			
20			
25			
30			
35			
40			
45			
50			
55			

	SEQUENCE LISTING	
	<pre><110> Fraunhofer-Gesellschaft zur Förderung der angewandten</pre>	
	Forschung e. V.	
	<120> Reprogramming cells toward a pluripotent state	
5	<130> FBP25769-A <160> 28	
	<170> PatentIn version 3.5	
	<210> 1	
	<211> 2098	
4.0	<212> DNA	
10	<213> Homo sapiens	
	<pre><400> 1 attataaatc tagagactcc aggattttaa cgttctgctg gactgagctg gttgcctcat 60</pre>	h
	gttattatgc aggcaactca ctttatccca atttcttgat acttttcctt ctggaggtcc 12	
	tatttctcta acatcttcca gaaaagtctt aaagctgcct taaccttttt tccagtccac 18	
15	ctettaaatt tttteeteet etteetetat actaacatga gtgtggatee agettgteee 24	
15	caaagcttgc cttgctttga agcatccgac tgtaaagaat cttcacctat gcctgtgatt 30	
	tgtgggcctg aagaaaacta tccatccttg caaatgtctt ctgctgagat gcctcacacg 36	
	gagactgtet etectettee tteeteeatg gatetgetta tteaggacag eeetgattet 42 tecaceagte eeaaggeaa acaaceeact tetgeagaga agagtgtege aaaaaaggaa 48	
	gacaaggtee eggteaagaa acagaagaee agaactgtgt tetetteeae ceagetgtgt 54	
20	gtactcaatg atagatttca gagacagaaa tacctcagcc tccagcagat gcaagaactc 60	
	tccaacatcc tgaacctcag ctacaaacag gtgaagacct ggttccagaa ccagagaatg 66	
	aaatctaaga ggtggcagaa aaacaactgg ccgaagaata gcaatggtgt gacgcagaag 72	
	gcctcagcac ctacctaccc cagcctttac tcttcctacc accagggatg cctggtgaac 78	
	ccgactggga accttccaat gtggagcaac cagacctgga acaattcaac ctggagcaac 84 cagacccaga acatccagtc ctggagcaac cactcctgga acactcagac ctggtgcacc 90	
25	caateetgga acaateagge etggaacagt eettetgga acaeteagae etggtgeace 90 caateetgga acaateagge etggaacagt eeettetata actgtggaga ggaatetetg 96	
	cagtectgea tgeagtteea gecaaattet cetgecagtg acttggagge tgeettggaa 10	
	gctgctgggg aaggccttaa tgtaatacag cagaccacta ggtattttag tactccacaa 10	
	accatggatt tattcctaaa ctactccatg aacatgcaac ctgaagacgt gtgaagatga 11	
	gtgaaactga tattactcaa tttcagtctg gacactggct gaatcettee tetecectee 12	
30	tcccatccct cataggattt ttcttgtttg gaaaccacgt gttctggttt ccatgatgcc 12	
	catccagtca atctcatgga gggtggagta tggttggagc ctaatcagcg aggtttcttt 13 tttttttttt ttcctattgg atcttcctgg agaaaatact ttttttttt tttttttga 13	
	aacggagtet tgetetgteg eccaggetgg agtgeagtgg egeggtettg geteactgea 14	
	ageteegtet ecegggttea egecattete etgeeteage etecegagea getgggaeta 15	
	caggegeeeg ceacetegee eggetaatat tttgtatttt tagtagagae ggggttteae 15	
35	tgtgttagec aggatggtet cgateteetg acettgtgat ceacecgeet eggeeteet 16	
	aacagctggg atttacaggc gtgagccacc gcgccctgcc tagaaaagac attttaataa 16 ccttggctgc cgtctctggc tatagataag tagatctaat actagtttgg atatctttag 17	
	ggtttagaat ctaacctcaa gaataagaaa tacaagtaca aattggtgat gaagatgtat 18	
	tcgtattgtt tgggattggg aggctttgct tattttttaa aaactattga ggtaaagggt 18	
40	taagetgtaa cataettaat tgatttetta eegtttttgg etetgttttg etatateeee 19	
40	taatttgttg gttgtgctaa tctttgtaga aagaggtctc gtatttgctg catcgtaatg 19	
	acatgagtac tgctttagtt ggtttaagtt caaatgaatg aaacaactat ttttccttta 20	
	gttgatttta ccctgatttc accgagtgtt tcaatgagta aatatacagc ttaaacat 20	98
	<210> 2	
45	<211> 1356	
10	<212> DNA	
	<213> Mus musculus	
	<400> 2	
	tctatcgcct tgagccgttg gccttcagat aggctgattt ggttggtgtc ttgctctttc 60	
50	tgtgggaagg ctgcggctca cttccttctg acttcttgat aattttgcat tagacattta 12 actcttcttt ctatgatctt tccttctaga cactgagttt tttggttgtt gcctaaaacc 18	
	ttttcagaaa teeetteett egecateaca etgacatgag tgtgggtett eetggtege 24	
	acagtttgcc tagttctgag gaagcatcga attctgggaa cgcctcatca atgcctgcag 30	
	tttttcatcc cgagaactat tcttgcttac aagggtctgc tactgagatg ctctgcacag 36	
	aggetgeete teetegeeet teetetgaag acetgeetet teaaggeage eetgattett 42	
55	ctaccagtcc caaacaaaag ctctcaagtc ctgaggctga caagggccct gaggaggagg 48	
	agaacaaggt ccttgccagg aagcagaaga tgcggactgt gttctctcag gcccagctgt 54 gtgcactcaa ggacaggttt cagaagcaga agtacctcag cctccagcag atgcaagaac 60	
	gegeneering gynengyttt engangenyn nytheetteny eettenythy htychdydde ou	

	tataataaat	tatassaata	agctataagc	aggettaagaa	ataatttaaa	2200222002	660
			aaaaaccagt				
			tatcccagca				
			tccatgtggg				
5			ccaacttgga				
			cagtcctgga				
			ctgcagcctt				
			gaagccacta				
			aactactctg				
	gcaacatctg	ggcttaaagt	cagggcaaag	ccaggttcct	tccttcttcc	aaatattttc	1200
10	atatttttt	taaagattta	tttattcatt	atatgtaagt	acactgtagc	tgtcttcaga	1260
	cactccagaa	gagggcgtca	gatcttgtta	cgtatggttg	tgagccacca	tgtggttgct	1320
			tcggaagagc				1356
		-					
	<210> 3						
	<211> 2358						
15	<212> DNA						
		us norvegicu	15				
	<400> 3	.ooz.ogzo					
		taatttaaa	tctttctctt	ttatagaaaa	accoacete	acttotttt	60
20			tctggacatt				
20			taactttttg				
			gacatgagcg				
			tctggggatt				
			caagtgtctg				
			gacctacctc				
25			cccgaggetg				
20			aagatgcgga				
			caaaggtacc				
			aagcaggtga				
			caatggttga				
	cagcgccggt	ggagtatccc	agcatccatt	gcagctattc	tcagggctat	ctgatgaacg	780
30	cgtctggaaa	ccttccagta	tggggcagtc	agacctggac	caacccaact	tggaacaacc	840
	agacctggac	caacccaacc	tggagcaacc	agacctggac	caacccaact	tggagcaacc	900
			tggtgtactc				
	ctccgctcca	taacttcggg	gaggactccc	tgcagcctta	tgtgccgttg	cagcaaaact	1020
	tctccgccag	tgatttggag	gcgaatttgg	aagccactag	ggaaagccag	gcgcatttta	1080
	gtaccccgca	agccttggaa	ttgttcctga	actactccgt	gaattctcca	ggcgaaatat	1140
35	gaggtttaca	caacaactgg	gcttaaagtc	agggcagggc	cagggtcagc	tttcttcctt	1200
	cttccaaaga	gttttatatt	gttcttattt	ttttttaat	tattatttg	tttttgtttt	1260
	ttgtttatca	aggtagggtt	tctctgtgtg	gttctggctg	tcctggaatt	cactctgtag	1320
			agagatctgc				
			tagtttttat				
10			gtttttgttt				
40		-	tggctctgta	-			
			ggactaaagg		-		
			agaaagcaaa				
			cccccgtgtt				
			tgggcttcgg				
45			tactccatac				
40			agggcettge				
			gtctttttag				
		-					
			aaagtataca				
	_		aaggatcacc		-	_	
50			tgtctaaata				
			taaagtctca				
			ttgcagttcc				
		-	gtaccatgat	aaaccagtgc	cagetggaet	agtttaaata	
	aaacactaat	tttaccca					2358
							
55	<210> 4						

55 <**21**

<210> 4 <211> 2518 <212> DNA

	<213> Homo	aaniona					
	<400> 4	Saprens					
	ctattaactt	gttcaaaaaa	gtatcaggag	ttgtcaaggc	agagaagaga	gtgtttgcaa	60
			gcctctttaa				
5			tgagccccag				
			tcggccagag ttttccccca				
			ccgcccgcct				
			cgagggtcgg				
			tggagacgga				
10			ccaccgcggc				
			tgaatgcctt				
			agatgcacaa				
			cggagaagcg acccggatta				
			acacgetgee				
15			tgggcgccgg				
	cagttacgcg	cacatgaacg	gctggagcaa	cggcagctac	agcatgatgc	aggaccagct	960
			gcctcaatgc				
			tgcagtacaa				
20			tgtcctactc				
20			agtccgaggc gccaggccgg				
			aacccgccgc				
			gcacggccat				
			aggggggaga				
25			aagaaacagc				
25			atcacccaca				
			aaaccgcgat ctatttttgt				
			agatetggag				
			ctttgcagga				
30			gaaaaaaatg				
	tatttatcga	gataaacatg	gcaatcaaaa	tgtccattgt	ttataagctg	agaatttgcc	1920
			ttcttgctga				
			aaaattattc aataagtact				
		-	tactaaattt			-	
35			taatttataa				
			tgaaattact				
			gatatttaa				
			gtattatttg				
			taacaggtac				
40	cacagtttga	gataaataaa	tttttgaaat	atggacactg	aaaaaaaaaa	aaaaaaaa	2518
	<210> 5						
	<211> 2457						
	<212> DNA						
	<213> Mus n	nusculus					
45	<400> 5						<u> </u>
			gtatcaggag				
			gcctctttaa ggagcccgag				
			gagagcgcct				
			aactattctc				
50	cgaggccccc	gcccgcggcc	cctgcatccc	ggcccccgag	cgcggccccc	acagtcccgg	360
			cgccggcggg			-	
			gccgccgggc				
			ggcgaccggc				
			catggtatgg ctcggagatc				
55			gccgttcatc				
			taaataccgg				

	aaggataagt	acacgcttcc	cggaggcttg	ctggcccccg	gcgggaacag	catggcgagc	840
	ggggttgggg	tgggcgccgg	cctgggtgcg	ggcgtgaacc	agcgcatgga	cagctacgcg	900
	cacatgaacg	gctggagcaa	cggcagctac	agcatgatgc	aggagcagct	gggctacccg	960
	cagcacccgg	gcctcaacgc	tcacggcgcg	gcacagatgc	aaccgatgca	ccgctacgac	1020
5						cggctcgccc	
	acctacagca	tgtcctactc	gcagcagggc	acccccggta	tggcgctggg	ctccatgggc	1140
						ctcccactcc	
						ccccggcgcc	
						ccagagcggc	
						agggctggac	
10						aggggtgcaa	
						ccgcagcgaa	
						ccgtgatgcc	
						ttttgtacag	
						tctggaggaa	
15						tcgcagggag	
						aaaaaaagtt	
						aatcaaatgt	
						ttgctgggtt	
						ttcggatttg	
						ggcaagaccg	
20						acttactgtt	
						atagcttttg	
						gtttgaaata	
	-		-			tcccccttt	
						gctgccgaga	
	atccatgtat	atatttgaac	taataccatc	cttataacag	ctacattttc	aacttaagtt	2400
25	tttactccat	tatgcacagt	ttgagataaa	taaatttttg	aaatatggac	actgaaa	2457
	<210> 6						
	<211> 2323						
	<212> DNA						
30	<212> DNA	ıs norvegicu	15				
30	<212> DNA	us norvegicu	15				
30	<212> DNA <213> Rattu <400> 6			gcctctttaa	gactagggct	gggagaaaga	60
30	<212> DNA <213> Rattu <400> 6 gtgtttgcaa	aaagggaaaa	gtactttgct			gggagaaaga ttccaaaaac	
30	<212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga	aaagggaaaa aaaagaaagg	gtactttgct agagaagttt	ggagcccgag	gcttaagcct	ttccaaaaac	120
30	<212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac	aaagggaaaa aaaagaaagg aatcgcggcg	gtactttgct agagaagttt gcccgaggag	ggagcccgag gagagcgact	gcttaagcct gttttttcat	ttccaaaaac cccaattgca	120 180
30 35	<212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc	gtactttgct agagaagttt gcccgaggag gcttcccccc	ggagcccgag gagagcgact aactattctc	gcttaagcct gttttttcat cgccagatct	ttccaaaaac cccaattgca ccgcgcaagg	120 180 2 4 0
	<212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt ccgtgcacgc	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc cgacgacccc	gtactttgct agagaagttt gcccgaggag gcttcccccc gcccgcggcc	ggagcccgag gagagcgact aactattctc cctgcatccc	gcttaagcct gttttttcat cgccagatct ggcccccgcg	ttccaaaaac cccaattgca ccgcgcaagg cgcggccccc	120 180 240 300
	<212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt ccgtgcacgc gcagtcccgg	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc cgacgacccc ccggggccgag	gtactttgct agagaagttt gcccgaggag gcttcccccc gcccgcggcc ggtcggcggc	ggagcccgag gagagcgact aactattctc cctgcatccc cgccggcggg	gcttaagcct gtttttcat cgccagatct ggcccccgcg ccgcgcccgc	ttccaaaaac cccaattgca ccgcgcaagg cgcggccccc gcccagcgcc	120 180 240 300 360
	<212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt ccgtgcacgc gcagtcccgg cgcatgtata	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc cgacgacccc ccggggccgag acatgatgga	gtactttgct agagaagttt gcccgaggag gcttcccccc gcccgcggcc ggtcggcggc gacggagctg	ggagcccgag gagagcgact aactattctc cctgcatccc cgccggcggg aagccgccgg	gcttaagcct gtttttcat cgccagatct ggcccccgcg ccgcgcccgc gccctcagca	ttccaaaaac cccaattgca ccgcgcaagg cgcggccccc gcccagcgcc agcttcgggg	120 180 240 300 360 420
	<212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt ccgtgcacgc gcagtcccgg cgcatgtata ggcggcggcg	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc cgacgacccc ccggggccgag acatgatgga gaggaggcaa	gtactttgct agagaagttt gcccgaggag gcttcccccc gcccgcggcc ggtcggcggc gacggagctg cgccacggcg	ggagcccgag gagagcgact aactattctc cctgcatccc cgccggcggg aagccgccgg gcggcgaccg	gcttaagcct gtttttcat cgccagatct ggcccccgcg ccgcgcccgc gccctcagca gcggcaacca	ttccaaaaac cccaattgca cgcgcgcaagg cgcggccccc gcccagcgcc agcttcgggg gaagaacagc	120 180 240 300 360 420 480
	<212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt ccgtgcacgc gcagtcccgg cgcatgtata ggcggcggcg ccggaccgcg	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc cgacgacccc ccgggccgag acatgatgga gaggaggcaa tcaagaggcc	gtactttgct agagaagttt gcccgaggag gcttcccccc gcccgcggcc ggtcggcggc gacggagctg cgccacggcg catgaatgcc	ggagcccgag gagagcgact aactattctc cctgcatccc cgccggcggg aagccgccgg gcggcgaccg ttcatggtgt	gcttaagcct gttttttcat cgccagatct ggcccccgcg ccgcgcccgc gccctcagca gcggcaacca ggtcccgggg	ttccaaaaac cccaattgca ccgcgcaagg cgcggccccc gcccagcgcc agcttcgggg gaagaacagc gcagcggcgt	120 180 240 300 360 420 480 540
	<212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt ccgtgcacgc gcagtcccgg cgcatgtata ggcggcggcg ccggaccgcg aagatggccc	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc cgacgacccc ccggggccgag acatgatgga gaggaggcaa tcaagaggcc aggagaaccc	gtactttgct agagaagttt gcccgaggag gcttcccccc gcccgcggcc ggtcggcggc gacggagctg cgccacggcg catgaatgcc caagatgcac	ggagcccgag gagagcgact aactattctc cctgcatccc cgccggcggg aagccgccgg gcggcgaccg ttcatggtgt aactcggaga	gcttaagcct gtttttcat cgccagatct ggcccccgcg ccgcgcccgc gccctcagca gcggcaacca ggtcccgggg tcagcaagcg	ttccaaaaac cccaattgca cgcgcgcaagg cgcggccccc gcccagcgcc agcttcgggg gaagaacagc gcagcggcgt cctgggcgcc	120 180 240 300 360 420 480 540 600
35	<212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt ccgtgcacgc gcagtcccgg cgcatgtata ggcggcggcg ccggaccgcg aagatggcaac gagtggaaac	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc cgacgacccc ccggggccgag acatgatgga gaggaggcaa tcaagaggcc aggagaaccc ttttgtcgga	gtactttgct agagaagttt gcccgaggag gcttcccccc gcccgcggcc ggtcggcggc gacggagctg cgccacggcg catgaatgcc caagatgcac gaccgagaag	ggagcccgag gagagcgact aactattctc cctgcatccc cgccggcggg aagccgccgg gcggcgaccg ttcatggtgt aactcggaga cggccgttca	gcttaagcct gttttttcat cgccagatct ggcccccgcg ccgcgcccgc gccctcagca ggtcccgggg tcagcaagcg tcgacgaggc	ttccaaaaac cccaattgca cgcgcgcaagg cgcggccccc gccagcgcc gaagaacagc gcagcggcgt cctgggcgcc caagcggcgt	120 180 240 300 360 420 480 540 600 660
35	<212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt ccgtgcacgc gcagtcccgg cgcatgtata ggcggcggcg ccggaccgcg aagatggcac gagtggaaac cgcgctctgc	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc cgacgacccc ccgggccgag acatgatgga gaggaggcaa tcaagaggcc aggagaaccc ttttgtcgga acatgaagga	gtactttgct agagaagttt gcccgaggag gcttcccccc gcccgcggcc gatcggcggc gacggagctg cgccacggcg catgaatgcc caagatgcac gaccgagaag gcaccgggat	ggagcccgag gagagcgact aactattete ectgcatece egeeggegg aagcegegg geggegaceg tteatggtgt aacteggaga eggeegtea tataaatace	gcttaagcct gttttttcat cgccagatct ggcccccgcg ccgcgcccgc gccctcagca ggtcccgggg tcagcaagcg tcgacgaggc ggccgcggcg	ttccaaaaac cccaattgca cgcgcaagg cgcggcccc gccagcgcc agcttcgggg gaagaacagc gcagcggcgt cctgggcgcc caagcggctg gaaaaccaag	120 180 240 300 360 420 480 540 600 660 720
35	<212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt ccgtgcacgc gcagtcccgg cgcatgtata ggcggcggcg ccggaccgcg aagatggccc gagtggaaac cgcgctctgc acgctctgc	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc cgacgacccc ccgggccgag acatgatgga gaggaggcaa tcaagaggcc aggagaaccc ttttgtcgga acatgaagga acatgaagga	gtactttgct agagaagttt gcccgaggag gcttcccccc gcccgcggcc ggtcggcggc gacggagctg cgccacggcg catgaatgcc caagatgcac gaccgagaag gcacccggat gtacacggtt	ggagcccgag gagagcgact aactattctc cctgcatccc cgccggcggg aagccgccgg gcggcgaccg ttcatggtgt aactcggaga cggccgttca tataaatacc cccggaggct	gcttaagcct gtttttcat cgccagatct ggcccccgcg gccctcagca ggtgcaacca ggtcccgggg tcagcaagcg tcgacgaggc ggccgcggcg tgctggcccc	ttccaaaaac cccaattgca cgcgcaagg cgcggcccc gcccagcgcc agcttcgggg gaagaacagc gcagcggcgt cctgggcgcc caagcggctg gaaaaccaag cggcgggaac	120 180 240 300 420 480 540 600 660 720 780
35	<212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt ccgtgcacgc gcagtcccgg cgcatgtata ggcggcggcg cggacgcgcg aagatggcac gagtggaaac cgcgctctgc acgctcatga agcatggcga	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc cgacgacccc ccgggccgag acatgatgga gaggaggcaa tcaagaggcc aggagaaccc ttttgtcgga acatgaagga acatgaagga acatgaagga	gtactttgct agagaagttt gcccgaggag gcttcccccc gcccgcggcc gatcggcggc cacgagactg caccacggcg catgaatgcc gaccgagaag gcacccggat gtacacggtt gtacacgctt	ggagcccgag gagagcgact aactattctc cctgcatccc cgccggcggg aagccgccgg gcggcgaccg ttcatggtgt aactcggaga cggccgttca tataaatacc cccggaggct ggcctgggtg	gcttaagcct gttttttcat cgccagatct ggcccccgcg gccctcagca gcggcaacca ggtcccgggg tcagcaagcg tcgacgaggc ggccgcggcg tgctggcccc cgggcgtgaa	ttccaaaaac cccaattgca cgcgcgcaagg cgcggccccc gcccagcgcc agcttcgggg gaagaacagc gcagcggcgt cctgggcgcc caagcggctg gaaaaccaag cggcgggaac ccagcgcatg	120 180 240 300 420 480 540 600 660 720 780 840
35 40	<212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt ccgtgcacgc gcagtcccgg cgcatgtata ggcggcggcg cggacgcgcg aagatggcac gagtggaaac cgcgctctgc acgctcatga agcatggcga gacagctacga	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc cgacgacccc ccgggccgag acatgatgga gaggaggcaa tcaagaggcc aggagaaccc ttttgtcgga acatgaagga acatgaagga agaaggataa gcggggttgg cgcacatgaa	gtactttgct agagaagttt gcccgaggag gcttcccccc gcccgcggcc gatcggcggc gacggagctg caccacggcg catgaatgccc gaccgagaag gcacccggat gtacacggtt gtacacgctt ggtgggcgcc cggctggagc	ggagcccgag gagagcgact aactattctc cctgcatccc cgccggcggg gcggcgaccg ttcatggtgt aactcggaga cggccgttca tataaatacc cccggaggct ggcctgggtg aacggcagct	gcttaagcct gtttttcat cgccagatct ggcccccgcg gccctcagca gcggcaacca ggtcccgggg tcagcaagcg tcgacgaggc ggccgcggcg tgctggcccc cgggcgtgaa acagcatgat	ttccaaaaac cccaattgca ccgcgcaagg cgcggccccc gcccagcgcc agcttcgggg gaagaacagc gcagcggcgt cctgggcgcc caagcggctg gaaaaccaag cggcgggaac ccagcgcatg gcaggagcag	120 180 240 300 420 480 540 600 660 720 780 840 900
35	<212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt ccgtgcacgc gcagtcccgg cgcatgtata ggcggcggcg cggacgcgcg aagatggcac gagtggaaac cgcgctctgc acgctcatga agcatggcga gacagctacga gacagctacg	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc cgacgacccc ccgggccgag acatgatgga gaggaggcaa tcaagaggcc aggagaaccc ttttgtcgga acatgaaga acatgaagga acatgaagga acatgaagga acatgaagga acatgaagga acatgaagga acatgaagga acatgaagga acatgaaga acatgaaga acatgaaga acatgaaga acatgaaccc	gtactttgct agagaagttt gcccgaggag gcttcccccc gcccgcggcc gatcggcggc gacggagctg cgccacggcg catgaatgcc gaccgagaag gcacccggat gtacacggtt gtacacgct ggtgggcgcc cggctggagc	ggagcccgag gagagcgact aactattctc cctgcatccc cgccggcggg gcggcgaccg ttcatggtgt aactcggaga cggccgttca tataaatacc cccggaggct ggcctgggtg aacggcagct ggcctgggtg	gcttaagcct gtttttcat cgccagatct ggcccccgcg gccctcagca gcggcaacca ggtcccgggg tcagcaggg tcgacgaggc ggccgcggcg tgctggcccc cgggcgtgaa acagcatgat	ttccaaaaac cccaattgca ccgcgcaagg cgcggccccc gcccagcgcc agcttcgggg gaagaacagc gcagcggcgt cctgggcgcc caagcggctg gaaaaccaag cggcgggaac ccagcgcatg gcaggagcag gcagcagatg	120 180 240 300 420 480 540 600 660 720 780 840 900 960
35 40	<212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt ccgtgcacgc gcagtcccgg cgcatgtata ggcggcggcg ccggaccgcg aagatggcaac cgcgctctgc acgctcatga agcatggcga gacagctacg ctgggctacc caccgctacg	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc cgacgacccc ccgggccgag acatgatgga gaggaggcaa tcaagaggcc aggagaaccc ttttgtcgga acatgaagga acatgaagga acatgaagga agaaggataa gcggggttgg cgcacatgaa cgcagcaccc	gtactttgct agagaagttt gcccgaggag gcttcccccc ggccgggcc gacggagctg cgccacggcg catgaatgcc caagatgcac gaccgagaag gcacccggat gtacacggtt gtagggcgcc cggctggagc gggcctcaac cctgcagtac	ggagcccgag gagagcgact aactattctc cctgcatccc cgccggcggg aagccgccgg gcggcgaccg ttcatggtgt aactcggaga cggccgttca tataaatacc cccggaggct ggcctgggtg aacggcagct gctcacggcg aaccgcgg	gcttaagcct gtttttcat cgccagatct ggcccccgcg gccctcagca gcggcaacca ggtcccgggg tcagcaggg tcgacgaggc ggccgcggcg tgctggcccc cgggcgtgaa acagcatgat ccagctcgca	ttccaaaaac cccaattgca ccgcgcaagg cgcggccccc gcccagcgcc agcttcgggg gaagaacagc gcagcggcgt cctgggcgcc caagcggctg gaaaaccaag cggcgggaac ccagcgcatg gcaggagcag gcagccgatg gacctacatg	120 180 240 300 420 480 540 600 660 720 780 840 900 960 1020
35 40	<212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt ccgtgcacgc gcagtcccgg cgcatgtata ggcggcggcg cggacggcg cggatggaaac cgcgctctgc acgctcatga agcatggcga gacagctacg ctgggctacc caccgctacg aacggctccgg	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc cgacgacccc ccgggccgag acatgatgga gaggaggcaa tcaagaggcc aggagaaccc ttttgtcgga acatgaagga acatgaagga agaaggataa gcggggttgg cgcacatgaa cgcagcaccc acgtcagcgc ccacctacag	gtactttgct agagaagttt gcccgaggag gcttcccccc gcccgcggcc gacggagctg cgccacggcg catgaatgcc caagatgcac gaccgagaag gcacccggat gtacacggt gtagggcgcc cggctggagc gggcctcaac cctgcagtac catgtcctac	ggagcccgag gagagcgact aactattctc cctgcatccc cgccggcggg aagccgccgg gcggcgaccg ttcatggtgt aactcggaga cggccgttca tataaatacc cccggaggct ggcctgggtg aacggcagct gctcacggcg aactccatga tcgcagcagg	gcttaagcct gtttttcat cgccagatct ggccccgcg gccctcagca gcggcaacca ggtcccgggg tcagcaggg tcgacgaggc ggccgcggcg tgctggcccc cgggcgtgaa acagcatgat ccagctcgca gcacccgg	ttccaaaaac cccaattgca ccgcgcaagg cgcggccccc gcccagcgcc agcttcgggg gaagaacagc gcagcggcgt cctgggcgcc caagcggctg gaaaaccaag cggcgggaac ccagcgcatg gcaggagcag gcagccgatg gacctacatg tatggcgctg	120 180 240 300 420 480 540 600 660 720 780 840 900 960 1020 1080
35 40	<212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt ccgtgcacgc gcagtcccgg cgcatgtata ggcggcggcg cggacggcg cggatggaaac cgcgctctgc acgctcatga agcatggcga gacagctacg ctgggctacc caccgctacg aacggctcgg ggctcatga	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc cgacgacccc ccgggccgag acatgatgga gaggaggcaa tcaagaggcc aggagaaccc ttttgtcgga acatgaagga acatgaagga agaaggataa gcggggttgg cgcacatgaa cgcagcaccc acgtcagcgc ccacctacag gctctgtggt	gtactttgct agagaagttt gcccgaggag gcttcccccc gcccgcggcc gacggagctg cgccacggcg catgaatgcc caagatgcac gaccgagaag gcacccggat gtacacggt gggcgcc caggetggagc catgatgcac caggetggagc catgactaac catgtcctaac caagtccgag	ggagcccgag gagagcgact aactattctc cctgcatccc cgccggcggg aagccgccgg gcggcgaccg ttcatggtgt aactcggaga caggccgttca tataaatacc cccggaggct ggcctgggtg aacggcagct gctcacggcg aactccatga tcgcagcagg gccagttcca	gcttaagcct gtttttcat cgccagatct ggccccgcg gccctcagca gcggcaacca ggtcccgggg tcagcaggg tcgacgaggc ggccgcggcg tgctggcccc cgggcgtgaa acagcatgat ccagctcgca gcccccgg gcccccgg	ttccaaaaac cccaattgca ccgcgcaagg cgcggccccc gcccagcgcc agcttcgggg gaagaacagc gcagcggcgt cctgggcgcc caagcggctg gaaaaccaag cggcgggaac ccagcgcatg gcaggagcag gcagccgatg gacctacatg tatggcgctg	120 180 240 300 420 480 540 600 660 720 780 840 900 960 1020 1080 1140
35 40	<212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt ccgtgcacgc gcagtcccgg cgcatgtata ggcggcggcg cggacgcgcg aagatggcaac cgcgctctgc acgctcatga agcatggcga gacagctacg ctgggctacc caccgctacg aacgctcatga agcaggctacg cggctcacg ccggctcacg ccggctcacg agcagctacg ccggctcacg ccggctcacg ccggctcacg ccggctcacg ccggctcacg ccggctcacg ccggctcacg ccggctcacg ccggctcacg ccggctcacg ccggctcacg ccggctcacg ccggctcacg ccggctacc caccgctacg ccgctcacg ccggctcacg ccggctcacg ccggctcacg ccggctcacg ccggctcacg ccggctcacg ccggctcacg ccggctacc caccgctacg ccggctcacg ccggctacc cccgctacg ccggctacc cccgctacg ccggctacc cccgctacg ccggctacc cccgctacg ccggctacc cccgctacg ccggctacc cccgctacg ccggctacc cccgctacg ccggctacc ccccgctacg ccggctacc ccccgctacg ccggctacc ccccgctacg ccggctacc ccccgctacg ccggctacc ccccgctacg ccggctacc ccccgctacg ccggctacc ccccgctacg ccggctacc ccccgctacg ccggctacc ccccgctacg ccggctacc ccccgctacg ccggctacc ccccgctacg ccggctacc ccccgctacg ccggctacc ccccgctacg ccgctacc ccccgctacg	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc cgacgacccc ccgggccgag acatgatgga gaggaggcaa tcaagaggcc aggagaaccc ttttgtcgga acatgaagga acatgaagga agaaggataa gcggggttgg cgcacatgaa cgcagcaccc acgtcagcgc ccacctacag gctctgtggt ccagggcgcc	gtactttgct agagaagttt gcccgaggag gcttcccccc gcccgcggcc gacggagctg cgccacggcg catgaatgcc caagatgcac gaccgagaag gcacccggat gtacacggt gggcctcaac ccggctggagc catgatccac caagtccgag gggcctcaac catgtcctac caagtccgag catgccaggc	ggagcccgag gagagcgact aactattctc cctgcatccc cgccggcggg aagccgccgg gcggcgaccg ttcatggtgt aactcggaga caggccgttca tataaatacc cccggaggct ggcctgggtg aacggcagct gctcacggcg aactccatga tcgcagcagg gccagttcca ggggacctcc	gcttaagcct gtttttcat cgccagatct ggcccccgc gccctcagca gcggcaacca ggtcccgggg tcagcaggg tcgacgaggc ggccgcggcg tgctggcccc cgggcgtgaa acagcatgat ccagctcgca gccccccgg gccccccgt gggacatgat	ttccaaaaac cccaattgca ccgcgcaagg cgcggccccc gcccagcgcc agcttcgggg gaagaacagc gcagcggcgt cctgggcgcc caagcggctg gaaaaccaag cggcgggaac ccagcgcatg gcaggagcag gcagccgatg gacctacatg tatggcgctg ggttacctct cagcatgtac	120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200
35 40 45	<212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt ccgtgcacgc gcagtcccgg cgcatgtata ggcggcggcg cggacgcgcg aagatggcaac cgcgctctgc acgctcatga agcatggcga gacagctacg ctgggctacc caccgctacg agcggctacg ccggaccgcg agcagtcacga gacagctcatga agcatggcga ccggctcacga ccgggctacc caccgctacg aacggctcacg caccgctacg aacggctcacg caccgctacg aacggctcacg caccgctacg aacggctcacg	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc cgacgacccc ccgggccgag acatgatgga gaggaggcaa tcaagaggcc aggagaaccc ttttgtcgga acatgaagga agaaggataa gcggggttgg cgcacatgaa cgcagcaccc acgtcagcgc ccacctacag gctctgtggt ccagggcgcc ccgaggtgcc	gtactttgct agagaagttt gcccgaggag gcttcccccc ggccgggcc gacggagctg cgccacggcg catgaatgcc caagatgcac gaccgagaag gcaccggga gtacacggat gtacacggt gggcctcaac cctgcagtac caagtccgag catgaccgag	ggagcccgag gagagcgact aactattctc cctgcatccc cgccggcggg aagccgccgg gcggcgaccg ttcatggtgt aactcggaga caggccgttca tataaatacc cccggaggct ggcctgggtg aacggcagct gctcacggcg aactccatga tcgcagcagg gccagttcca ggggacctcc gggccagta	gcttaagcct gtttttcat cgccagatct ggcccccgcg gccctcagca ggtcccgggg tcagcaacca ggtcccgggg tcgacgaggc ggccgcggcg tgctggcccc cgggcgtgaa acagcatgat ccagctcgca gccccccgg ggccccccgt gggacatgat gactgcacat	ttccaaaaac cccaattgca ccgcgcaagg cgcggccccc gcccagcgcc agcttcgggg gaagaacagc gcagcggcgt cctgggcgcc caagcggctg gaaaaccaag cggcgggaac ccagcgcatg gcagcagag gcagccgatg gacctacatg tatggcgctg ggttacctct cagcatgtac ggcccagcac	120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260
35 40	<212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt ccgtgcacgc gcagtcccgg cgcatgtata ggcggcggcg cggacgcgcg aagatggcaac cgcgctctgc acgctcatga agcatggcga gacagctacg ctgggctacc caccgctacg agcggctacg ccggaccgcg agcagtcacga gacagctcatga agcatggcga ccggctcacga ccgggctacc caccgctacg aacggctcacg caccgctacg aacggctcacg caccgctacg aacggctcacg caccgctacg aacggctcacg	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc cgacgacccc ccgggccgag acatgatgga gaggaggcaa tcaagaggcc aggagaaccc ttttgtcgga acatgaagga agaaggataa gcggggttgg cgcacatgaa cgcagcaccc acgtcagcgc ccacctacag gctctgtggt ccagggcgcc ccgaggtgcc	gtactttgct agagaagttt gcccgaggag gcttcccccc ggccgggcc gacggagctg cgccacggcg catgaatgcc caagatgcac gaccgagaag gcaccggga gtacacggat gtacacggt gggcctcaac cctgcagtac caagtccgag catgaccgag	ggagcccgag gagagcgact aactattctc cctgcatccc cgccggcggg aagccgccgg gcggcgaccg ttcatggtgt aactcggaga caggccgttca tataaatacc cccggaggct ggcctgggtg aacggcagct gctcacggcg aactccatga tcgcagcagg gccagttcca ggggacctcc gggccagta	gcttaagcct gtttttcat cgccagatct ggcccccgcg gccctcagca ggtcccgggg tcagcaacca ggtcccgggg tcgacgaggc ggccgcggcg tgctggcccc cgggcgtgaa acagcatgat ccagctcgca gccccccgg ggccccccgt gggacatgat gactgcacat	ttccaaaaac cccaattgca ccgcgcaagg cgcggccccc gcccagcgcc agcttcgggg gaagaacagc gcagcggcgt cctgggcgcc caagcggctg gaaaaccaag cggcgggaac ccagcgcatg gcaggagcag gcagccgatg gacctacatg tatggcgctg ggttacctct cagcatgtac	120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260
35 40 45	<212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt ccgtgcacgc gcagtcccgg cgcatgtata ggcggcggcg ccggaccgcg aagatggccc gagtggaaac cgcgctctgc acgctcatga agcatggcga gacagctacg ctgggctacc caccgctacg agcgcgcacgcg agcagctcacg ccggaccgcg acgctcatga agcatggcga ccgcacacgcacg ccgcacacgcacg ccgcacacgcacg	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc ccgacgacccc ccgggccgag acatgatgga gaggaggcaa tcaagaggcc aggagaaccc ttttgtcgga acatgaagga acatgaagga agaaggataa gcggggttgg cgcacatgaa cgcagcaccc acgtcagcgc ccacctacag gctctgtggt ccagggcgcc gcccggtgcc	gtactttgct agagaagttt gcccgaggag gcttcccccc ggccgggcc gacggagctg cgccacggcg catgaatgcc gaccgagaag gcaccggagaag gcaccggagaag gtacacggt gggcgccc cggctggagc gggcctcaac cctgcagtac catgtcctac caagtccgag ctgccaggcc ggagcccgct cggcaggcc	ggagcccgag gagagcgact aactattete cetgeateee cgeeggeggg gagcggeggg geggegaceg tteatggtgt aacteggaga cggeegtea tataaataee ggeetgggtg aacggeaget geteaeggeg aacteatga tegeageagg geeagtteea ggggaeetee gegeeeagta attaaeggea	gcttaagcct gtttttcat cgccagatct ggcccccgcg gccctcagca gggcaacca ggtcccgggg tcagcaagcg ggccgcgggg tgctggcgcg tgctggcccc cgggcgtgaa acagcatgat ccagccccgg ggccccccgg ggccccccgt gggacatgat gactgcacat	ttccaaaaac cccaattgca ccgcgcaagg cgcggccccc gcccagcgcc agcttcgggg gaagaacagc gcagcggcgt cctgggcgcc caagcggctg gaaaaccaag cggcgggaac ccagcgcatg gcagcagag gcagccgatg gacctacatg tatggcgctg ggttacctct cagcatgtac ggcccagcac	120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320
35 40 45	<212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt ccgtgcacgc gcagtcccgg cgcatgtata ggcggcggcg ccggaccgcg aagatggccc gagtggaaac cgcgctctgc acgctcatga agcatggcga gacagctacg ggctcatga gacagctacg ctgggctacc caccgctacg aacggctcg ggctccatgg tcctcccact ctccccggcg taccagagcg tgagggccgg	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc cgacgacccc ccgggccgag acatgatgga gaggaggcaa tcaagaggcc aggagaaccc ttttgtcgga acatgaagga agaaggataa gcggggttgg cgcacatgaa cgcagcaccc acgtcagcgc ccacctacag gctctgtggt ccagggcgcc acgggtgcc accgggtgcc accgcgaact	gtactttgct agagaagttt gcccgaggag gcttcccccc ggccgggcc gacggagctg cgccacggcg catgaatgcc gaccgagaag gcaccggagaag gcacccggat gtagggcgcc cggctggagc gggcctcaac cctgcagtac catgtcctac caagtccgag catgaccggag gggccccac ggagccgct ggagccgc ggagccgc ggagccgc ggagccgc ggagaagggg	ggagcccgag gagagcgact aactattete cetgcatece cgecggeggg gagcggeggg geggegaceg tteatggtgt aacteggaga cggeegttea tataaatace ceeggagget ggeetgggtg aacggeaget geteaegge geeagtteea ggggaeetee gegeeeagta attaaeggea agagatttt	gcttaagcct gtttttcat cgccagatct ggcccccgcg ccgcgcccgc gcctcagca ggtcccgggg tcagcaagcg ggccgcgggg tgctggcgcg cggcgtgaa acagcatgat ccagccccgg ggccccccgg ggccccccgt gggacatgat cactgccct caaaaagata	ttccaaaaac cccaattgca ccgcgcaagg cgcggccccc gcccagcgcc agcttcgggg gaagaacagc gcagcggcgt cctgggcgcc caagcggctg gaaaaccaag cggcgggaac ccagcgcatg gcaggagcag gcagccgatg gacctacatg tatggcgctg ggttacctct cagcatgtac ggcccagcac ggcccagcac	120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380
35 40 45	<pre><212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt ccgtgcacgc gcagtcccgg cgcatgtata ggcggcggcg cggatggaaac cgcgctctgc acgctcatga agcatggcga gacagctacg ggctcacgc ggctcatga agcatggcga ccgggctacc caccgctacg acgctcatgg tcctcccact caccgcgg tcccagggg ccggaggggg gggagggggg gggagggggggg</pre>	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc cgacgacccc ccgggccgag acatgatgga gaggaggcaa tcaagaggcc attttgtcgga acatgaagga acatgaagga agaaggataa gcggggttgg cgcacatgaa cgcagcaccc acgtcagcgc ccacctacag gctctgtggt ccagggcgcc acgggtgcc gcccggtgcc accgcgaact caaaagagga	gtactttgct agagaagttt gcccgaggag gcttcccccc ggccgggcc gacggagctg cgccacggcg catgaatgcc gaccgagaag gcaccggagaag gcacccggat gtacacgctt ggtgggcgcc cggctggagc gggcctcaac cctgcagtac catgtcctac caagtccgag ctgccaggcc ggagccgct ggagccgct ggagccgct ggagacggc gggcccgat	ggagcccgag gagagcgact aactattete cetgcatece cgccggeggg aagcegeegg geggegaceg tteatggtgt aacteggaga cggcegttea tataaatace ceeggagget ggeetgggtg aacggeaget geteaeggeg aacteatga tegeageagg geeagtteea ggggaeetee gegeeeagta attaaeggea attaaeggea	gcttaagcct gtttttcat cgccagatct ggcccccgcg gccctcagca gggcaacca ggtcccgggg tcagcaagcg ggccgcgggg tgctggcgcg tgctggcccc cgggcgtgaa acagcatgat ccagccccgg ggccccccgg ggccccccgt gggacatgat cactgccct caaaaagata ctcaaaagga	ttccaaaaac cccaattgca ccgcgcaagg cgcggccccc gcccagcgcc agcttcgggg gaagaacagc gcagcggcgt cctgggcggc gaaaaccaag cggcgggaac ccagcgcatg gcagcaggagcag gcagccgatg gacctacatg tatggcgctg ggttacctct cagcatgtac ggcccagcac gtcgccacatg aaaaaaaat	120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440
35 40 45	<pre><212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt ccgtgcacgc gcagtcccgg cgcatgtata ggcggcggcg ccggaccgcg aagatggccc gagtggaaac cgcgctctgc acgctcatga agcatggcga gacagctacg ggctcatgg tcccccact ctccccggcg tccccggg ccggacggg ggctcatgg aagatggccc ggctcatgg cagctcatgg ctcggctacc caccgctacg aacggctcgg ggctccatgg tcctcccact ctccccggcg tgagggccgg gggaggggtg ccattaccc</pre>	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc cgacgacccc ccgggccgag acatgatgga gaggaggcaa tcaagaggcc aggagaaccc ttttgtcgga acatgaagga agaaggataa gcggggttgg cgcacatgaa cgcagcaccc acgtcagcgc ccacctacag gctctgtggt ccagggcgcc gcccggtgcc accgcgaact caaaagagga gcagcaaaat	gtactttgct agagaagttt gcccgaggag gcttcccccc ggccgggcc gacggagctg cgccacggcg catgaatgcc caagatgcac gaccgagaag gcacccggat gtacacggtt ggtgggcgcc cggctggagc gggcctcaac cctgcagtac caagtccgag ctgccaggcc ggagcccgct cggaggccgc ggagccgct ggagacggc ggagaagggg gagtaagaaa gacagctgcg	ggagcccgag gagagcgact aactattete cetgcatece cgccggeggg aagcegeegg geggegaceg tteatggtgt aacteggaga cggcegttea tataaatace eceggagget ggeetgggtg aacggeaget geteaegge geeagtteea ggggacetee gegeeeagta attaaeggea attaaeggea gagaattett aatetgaatg gaaaaaaece	gcttaagcct gtttttcat cgccagatct ggcccccgcg ccgcgcccgc gcctcagca ggtcccgggg tcgacgaggc ggccgcgggg tgctggcgcg cgggcgtgaa acagcatgat ccagctcgca gccccccgg gccccccgg ggcccccgg ggccccccgt gggacatgat cactgccct caaaaagata ctcaaaagga accaatccca	ttccaaaaac cccaattgca ccgcgcaagg ggcggccccc gcccagcggc gaagaacagc gcagcggggt cctgggcgcc caagcggctg gaaaaccaag ggcggggaac ccagcgcatg gcaggagcag gacctacatg tatggcgctg ggttacctct cagcatgtac ggcccagcac ggcccagcac ggcccagcac gtcgcacatg	120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1320 1380 1440 1500
35 40 45 50	<pre><212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt ccgtgcacgc gcagtcccgg cgcatgtata ggcggcggcg ccggaccgcg aagatggccc gagtggaaac cgcgctctgc acgctcatga agcatggcga gacagctacg ggctcatgg tcctcccact ctccccggcg tccccggg tccccggg ccggacggg ggctcatga agcatggcga ccgcatacg ccggacagca ccgcgctctgc acgctcatga agcatggcga gccggtccc caccgctacg tcccccact ctccccggcg tcccccact ctccccggcg tccataccc cgcaaaaacc</pre>	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc cgacgacccc ccgggccgag acatgatgga gaggaggcaa tcaagaggcc aggagaaccc ttttgtcgga acatgaagga agaaggataa gcggggttgg cgcacatgaa cgcagcaccc acgtcagcgc ccacctacag gctctgtggt ccagggcgcc gcccggtgcc accgcgaact caaaagagga gcagcaaaat gtgatgccga	gtactttgct agagaagttt gcccgaggag gcttcccccc ggccgggcc gacggagctg cgccacggcg catgaatgcc caagatgcac gaccgagaag gcacccggat gtacacgctt ggtgggcgcc cggctggagc gggcctcaac cctgcagtac caagtccgag ctgccaggcc ggagcccgct ggagaccgct ggagacggc ggagcacgct cggcaggcc ggagaagggg gagtaagaaa gacagctgcg	ggagcccgag gagagcgact aactattete cetgcatece cgecggeggg gagcggeggg geggegaceg tteatggtgt aacteggaga cggeegtea tataaatace ceeggagget ggeetgggtg aacggeaget geteaegg geeagtteea ggggacetee gegeeeagta attaaeggea attaaeggea tegaggaget gegeeeagta attaaeggea tegaggaettete ggggaeetee gegeeeagta attaaeggea tteatggagg tteatggagg geeagtteea ggggaeetee gegeeeagta attaaeggea tteatgaatg gaaaaaaace tttatgagag	gcttaagcct gtttttcat cgccagatct ggcccccgcg ccgcgcccgc gcctcagca ggtcccgggg tcagcaagcg ggccgcgggg tgctggcgc cgggcgtgaa acagcatgat ccagctcgca ggcccccgg ggcccccgg ggcccccgg ggcccccgg ggcccccga ccagctcgca ccagctcgca ccagctcgca dcactgcacat cactgcccct caaaaagata ctcaaaagga accaatccca atctggagga	ttccaaaaac cccaattgca ccgcgcaagg ggcggccccc gcccagcggc gaagaacagc gcagcggggt cctggggggc caagcggctg gaaaaccaag ggcggggaac ccagcgcatg gcaggaggaag gcagccgatg ggttacctct cagcatgtac ggcccagcac ggcccagcac ggcccagcac gtcgccacatg tatggcgctg aaaacaac	120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1320 1380 1440 1500 1560
35 40 45	<pre><212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt ccgtgcacgc gcagtcccgg cgcatgtata ggcggcggcg ccggaccgcg aagatggccc gagtggaaac cgcgctctgc acgctcatga agcatggcga gacagctacg ggctcatgg tcctcccact ctccccggcg tccccggg tccccggg ccggacggg ggctcatga agcatggcga gacagctacg cggctcatgg tcctcccact ctccccggcg tgagggccgg gggaggggtg ctcattaccc cgcaaaaacc gcaaaacttt</pre>	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc cgacgacccc ccgggccgag acatgatgga gaggaggcaa tcaagaggcc aggagaaccc ttttgtcgga acatgaagga acatgaagga agaaggataa gcggggttgg cgcacatgaa cgcagcaccc acgtcagcgc ccacctacag gctctgtggt ccagggcgcc accgcgaact caaaagagga gcagcaaaat gtgatgccga tttttaaagt	gtactttgct agagaagttt gcccgaggag gcttcccccc gcccgcggcc gacggagctg cgccacggcg catgaatgcc caagatgcac gaccgagaag gcacccggat gtacacgctt ggtgggcgcc caggctggagc gggcctcaac cctgcagtac caagtccgag ctgccaggcc ggagcccgct cggaagggc ggagcacgct cggcacggc ggagaagggg gagtaagaaa gacagctgcg	ggagcccgag gagagcgact aactattete cetgcatece cgccggegg gcggcgaceg tteatggtgt aacteggaga cggcegttea tataaatace ceeggagget ggeetgggtg aacggeaget geteaegge geeagtteea ggggacetee gegeeeagta attaaeggea attaaeggea cggaaattttt aatetgaatg gaaaaaace tttatgagag cgttaggege	gcttaagcct gtttttcat cgccagatct ggcccccgcg gccctcagca gggcaacca ggtcccgggg tcgacgaggc ggccgcgggg tgctggcgcg tgctggcccc cgggcgtgaa acagcatgat ccagctcgca gccccccgg gccccccgg ggccccccgt gggacatgat cactgcccct caaaaagata ctcaaaagga acccatccca atctggagga	ttccaaaaac cccaattgca ccgcgcaagg ggcggccccc gcccagcggc gaagaacagc gcagcggggt cctgggcgcc caagcggctg gaaaaccaag gggggggaac ccagcgcatg gcaggaggaag gacctacatg tatggcgctg ggttacctct cagcatgtac ggcccagcac gtcgcacatg tatagggaatt aaaaaaaat tccaaattaa aaaaactac gtctccaaaa	120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1320 1380 1440 1500 1560 1620
35 40 45 50	<pre><212> DNA <213> Rattu <400> 6 gtgtttgcaa agaggagaga taatcacaac cttcgcccgt ccgtgcacgc gcagtcccgg cgcatgtata ggcggcggcg ccggaccgcg aagatggccc gagtggaaac cgcgctctgc acgctcatga agcatggcga gacagctacg ggctcatgg tcctcccact ctccccggcg tccccggg tccccggg ccggacggg ggctcatga agcatggcga ggctcatgg tcctcccact ctccccggcg tgagggccgg gggaggggtg ccgaaaacttt gtctttacca</pre>	aaagggaaaa aaaagaaagg aatcgcggcg ctcgagctcc cgacgacccc ccgggccgag acatgatgga gaggaggcaa tcaagaggcc aggagaaccc ttttgtcgga acatgaagga agaaggataa gcggggttgg cgcacatgaa cgcagcaccc acgtcagcgc ccacctacag gctctgtggt ccagggcgcc gcccggtgcc accgcgaact caaaagagga gcagcaaaat gtgatgccga tttttaaagt gtaatattta	gtactttgct agagaagttt gcccgaggag gcttcccccc gcccgcggcc gacggagctg cgccacggcg catgaatgcc caagatgcac gaccgagaag gcacccggat gtacacgctt ggtgggcgcc caggctggagc gggcctcaac cctgcagtac caagtccgag ctgccaggcc ggagcccgct cggaagaggg gagtaagaaa gacagctgcg ctagaaact tctagtggta	ggagcccgag gagagcgact aactattete cetgcatece cgccggcggg gcggcgaccg tteatggtgt aacteggaga cggcegttea tataaatace cccggagget gactggggg aacgecgttea ggectgggtg aacggeaget geteaeggg gccagtteea ggggacetee ggggacetee gegeeeagta attaaeggea attaatgagg gaaaaaaace tttatgagg cgttaggege ccgggegatg	gcttaagcct gtttttcat cgccagatct ggcccccgcg ccgcgcccgc gccctcagca ggtcccgggg tcgacgaggc ggccgcgggg tgctggcgcg cggcgtgaa acagcatgat ccggcacagat ccagctcgca gccccccgg ggccccccgt gggacatgat cactgcccct caaaaagata ctcaaaagaa accaatccca atctggagga aaaaaagtt	ttccaaaaac cccaattgca ccgcgcaagg ggcggccccc gcccagcggc gaagaacagc gcagcggggt cctggggggc caagcggctg gaaaaccaag ggcggggaac ccagcgcatg gcaggaggaag gcagccgatg ggttacctct cagcatgtac ggcccagcac ggcccagcac ggcccagcac gtcgccacatg tatggcgctg aaaacaac	120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1320 1380 1440 1500 1560 1620

5	gcttaaatta tttaaaattg ttgtttaggg aaaaatgtcc ccttttcatt gtttgtaata agttgtattt atttgaacta	aggaccgtta tacaaaagga caaacgttct atgcaggttg ttgttcacat tttctgtaaa taaaagattc	cagacaagga aaacatgaga agattgtact atatcgttgg aaaaatatgg ttgtgatatt ggctgttatt tataacagtt	aggaatttat gcaagtactg aaattttaa taatttataa aaattactgt ttaaggtttt ggaaccaggc acgtttccaa	tcggatttga gcaagaccat cttactgtta tagcttttgt gtttgaaata ttcccccttt tgccgagaat cttaagtttt	tgattctgca acgttttagt tttcgtggtc aaggcaaaaa tcaatcccac ttttcttatg tattttccgt ccatgtatat tactccatta	1860 1920 1980 2040 2100 2160 2220
	<210> 7 <211> 1411 <212> DNA <213> Homo <400> 7	sapiens					
15	ccttcgcaag ggacacctgg gggggggccgg ggagggccag	cttcggattt agccgggctg gaatcgggcc	cgccttctcg ggttgatcct ggggggttggg	ccccctccag cggacctggc ccaggctctg	gtggtggagg taagcttcca aggtgtgggg	ccccatggcg tgatgggcca aggccctcct gattccccca ggttggagtg	120 180 240
20	gtggagagca aagctggaga cagaaagaac acacaggccg	actccgatgg aggagaagct tcgagcaatt atgtggggct	ggcctccccg ggagcaaaac tgccaagctc caccctgggg	gagccctgca ccggaggagt ctgaagcaga gttctatttg	ccgtcacccc cccaggacat agaggatcac ggaaggtatt	aggagtcggg tggtgccgtg caaagctctg cctgggatat cagccaaacg gctgcggccc	420 480 540 600
25	ttgctgcaga gcagaaaccc ggcaacctgg atcgcccagc cagaagggca	agtgggtgga tcgtgcaggc agaatttgtt agcttgggct agcgatcaag	ggaagetgae cegaaagaga cetgeagtge egagaaggat cagegaetat	aacaatgaaa aagcgaacca ccgaaaccca gtggtccgag gcacaacgag	atcttcagga gtatcgagaa cactgcagca tgtggttctg aggattttga	gatatgcaaa ccgagtgaga gatcagccac taaccggcgc ggctgctggg	720 780 840 900 960
30	ccaggctatg gaagcctttc gcctgccctt agtttgtgcc	ggagccctca cccctgtctc ctaggaatgg agggtttttg	cttcactgca cgtcaccact gggacagggg ggattaagtt	ctgtactcct ctgggctctc gaggggagga cttcattcac	cggtcccttt ccatgcattc gctagggaaa taaggaagga	ttttggtacc ccctgagggg aaactgaggt gaaaacctgg attgggaaca agttcaatga	1080 1140 1200 1260
35	tgctcttgat		catcatgtat	cactttttc		aagcctggga	
40	<213> Mus m <400> 8 aaccgtccct catggctgga	aggtgagccg cacctggctt	cagacttcgc	cttctcaccc	ccaccaggtg	ccaccttccc ggggtgatgg tccaagggcc	120
45	tccaggtggg cgcatacgag cccccaagtt caactcagag gaaggtggaa	cctggaatcg ttctgcggag ggcgtggaga ggaacctcct ccaactcccg	gaccaggctc ggatggcata ctttgcagcc ctgagccctg aggagtccca	agaggtattg ctgtggacct tgagggccag tgccgaccgc ggacatgaaa	gggatctccc caggttggac gcaggagcac cccaatgccg gccctgcaga	catgtccgcc tgggcctagt gagtggaaag tgaagttgga aggagctaga	240 300 360 420 480
50	ggggctcacc cgaggccttg ggtggaggaa gcaggcccgg	ctgggcgttc cagctcagcc gccgacaaca aagagaaagc	tctttggaaa ttaagaacat atgagaacct gaactagcat	ggtgttcagc gtgtaagctg tcaggagata tgagaaccgt	cagaccacca cggcccctgc tgcaaatcgg gtgaggtgga	aggccgacgt tctgtcgctt tggagaagtg agaccctggt gtctggagac ccaatcagct	600 660 720 780
55	tgggctagag atcaagtatt	aaggatgtgg gagtattccc	ttcgagtatg aacgagaaga	gttctgtaac gtatgaggct	cggcgccaga acagggacac	agggcaaaag ctttcccagg gctatggaag	900 960

	cccccacttc	accacactct	actcagtccc	ttttcctgag	ggcgaggcct	ttccctctqt	1080
		gctctgggct					
		ccaaggcaag					
		gagggattaa					
5		gttgatcagg					
Ū		cacacagtag		5	2		1346
	5 555		5				
	<210> 9						
	<211> 2949						
	<212> DNA						
10	<213> Homo	sapiens					
	<400> 9	-					
	agtttcccga	ccagagagaa	cgaacgtgtc	tgcgggcgcg	cggggagcag	aggcggtggc	60
	gggcggcggc	ggcaccggga	gccgccgagt	gaccctcccc	cgcccctctg	gccccccacc	120
	ctcccacccg	cccgtggccc	gcgcccatgg	ccgcgcgcgc	tccacacaac	tcaccggagt	180
15	ccgcgccttg	cgccgccgac	cagttcgcag	ctccgcgcca	cggcagccag	tctcacctgg	240
	cggcaccgcc	cgcccaccgc	cccggccaca	gcccctgcgc	ccacggcagc	actcgaggcg	300
	accgcgacag	tggtggggga	cgctgctgag	tggaagagag	cgcagcccgg	ccaccggacc	360
	tacttactcg	ccttgctgat	tgtctatttt	tgcgtttaca	acttttctaa	gaacttttgt	420
		actttttaaa					
20		tttggggttt					
20		ccagctgctt					
		gcgagtctga					
		gcccggcggg					
		aggagctctc		-			
		cggcggcgac					
25		gcaacctggc					
		actttattct					
		cgtcagcgtc					
		ccacctgcag					
		gcacgggcgg					
30		acctggcgga					
		cagaattgga					
		tgggcaagtt					
		cggtcatcag acaacggcgg					
		cccacttggg					
		ccctggggcg					
35		gcagcaggga					
		ccaattaccc					
		aagageteat					
		gatcgtggcc					
		cctacacaaa					
40		accactgtga					
		actaccgtaa					
		ccaggtcgga					
		atgacccaca					
	tcttcccgat	gagggaagga	gcccagccag	aaagcactac	aatcatggtc	aagttcccaa	2160
45	ctgagtcatc	ttgtgagtgg	ataatcagga	aaaatgagga	atccaaaaga	caaaaatcaa	2220
10	agaacagatg	gggtctgtga	ctggatcttc	tatcattcca	attctaaatc	cgacttgaat	2280
	attcctggac	ttacaaaatg	ccaagggggt	gactggaagt	tgtggatatc	agggtataaa	2340
		gagttggggg					
	tataagcata	aaagatcacc	ttgtattctc	tttaccttct	aaaagccatt	attatgatgt	2460
		ggaagaaatt					
50		cttggttcta					
		aaggaaaatc					
		ggtttacttc					
		caataatttg		-	-		
		tatatagttc					
55	-	tatttgtaaa	-	-			
	-	gtgagaatta	agttttaaat	aaacctataa	tattttatct	gaaaaaaaaa	
	aaaaaaaaa						2949

	<210> 10						
	<211> 3057 <212> DNA						
	<212> DNA <213> Mus mus	culus					
5	<400> 10	Curus					
5	agttccccgg co	aagagagc	gagcgcggct	ccaaacacac	ggggggggggg	aacaataaca	60
	ggcggcggcg gc						
	gcaacccgcc cg						
	gcaccccgcg cc	caccgccca	gctcgcagtt	ccgcgccacc	gcggccattc	tcacctggcg	240
10	gegeegeeeg ee						
10	gacaacggtg gg						
	atctgccttg ct				-	-	
	tacaaaggaa ct						
	cgggcaatct gg						
	tttgggggtt ag						
15	attaatgagg ca cttctccacg tt						
	cccgactaac cg						
	ccgcccctac ga						
	agettgeage ag						
	cctcctggac ct						
20	caccgtgacc ac						
	cagegegece to						
	ggctgccagc aa						
	ggcccccttc aa						
	geteetgegg co	cggagttgg	acccagtata	cattccgcca	cagcagcctc	agccgccagg	1260
	tggcgggctg at	gggcaagt	ttgtgctgaa	ggcgtctctg	accacccctg	gcagcgagta	1320
25	cagcagccct to	cggtcatca	gtgttagcaa	aggaagccca	gacggcagcc	accccgtggt	1380
	agtggcgccc ta						
	cccgtcctgc ac						
	caacggccac cg						
	tacccctaca ct						
30	tcttccccca gg						
	gatgcagtca ca						
	gccagaggag co						
	ccacacttgt ga						
	acacctgcga ac gaaattcgcc cg						
35	ctttcagtgc ca				-		
00	gaagaggcac tt						
	cagtatttt tt						
	aagcgctaca at						
	aaggaagagt to						
	aaaaaaacaa ga						
40	tcattccaat ac						
	tggaagtttg tg	gatatcag	ggtatacact	aaatcagtga	gcttgggggg	agggaagacc	2460
	aggattccct to						
	tetttgeett et						
	aggtacagaa ca	-	-				
45	gtaccaaacg gg						
	gttttgtctt co						
	gtaacatttt ta						
	acaatggttt at						
	cttgccttaa ta						
50	ctacaaagta aa						
50	aaataagttt ta	aataaacc	ταταατατττ	tatctgaacg	acaaaaaaaa	aaaaaaa	3057
	<210> 11						
	<210> 11 <211> 2393						
	<211> 2393 <212> DNA						
	<213> Rattus norvegicus						
55	<400> 11		-				
	atcttcgttg ac	ttcgaaat	ttgggtaccc	ctctctcttc	ttcggactcc	ggaggacctt	60
		55555			<u> </u>		

tocagcaggt gccccgacta accgttggcg agaggaactc totcacatga agcgacttcc 240 cccacttccc ggccgcccct acgacctggc ggcgacggtg gccacagacc tggaaagtgg 300 tggagctggt gcagcttgca gcagtaacaa cccggcccta ccccggaggg agaccgagga 360 5 gttcaacgat ctcctggacc tagactttat cctttccaac tcgctatccc accaggaatc 420 ggtggccgcc accgtgacca cctcggcgtc agcttcatcc tcgtcttccc cagctagcag 480 cggccctgcc agcgcgccct ccacctgcag cttcagctat ccgatccggg ccgggggtga 540 cccgggcgtg gctgcgggca acacaggtgg agggctcctc tacagccgag aatctgcgcc 600 accteccacg gececettca acctggegga cateaatgae gtgageeeet egggeggett 660 10 cgtggctgag ctcctgcggc cggagttgga cccagtatac attccgccac agcagcctca 720 gccgccaggt ggcgggctga tgggcaagtt tgtgctgaag gcgtctctga gcacccctgg 780 cagcgagtac accagccctt cggtcatcag tgttagcaaa ggaagcccag acggcagcca 840 ccctgtggta gtggcgccct acagcggtgg cccgccgcgt atgtgcccca agattaagca 900 agaggccgtc ccgtcctgca cggtcagccg gtccctagag gcccacttga gcgctggacc 960 ccagctcagc aacggccaca ggcccaacac acacgacttc cccctggggc ggcagctccc 1020 15 caccaggact acccctacac tgagtcccga ggaactgctg aacagcaggg actgtcaccc 1080 tggcctgcct cttcccccag gattccatcc ccatccgggg cccagctacc ctcctttcct 1140 gccagaccag atgcagtcgc aagtcccctc tctccattat caagagctca tgccaccggg 1200 atcctgcctg ccagaggagc ccaagccaaa gaggggaaga aggtcttggc cccggaaaag 1260 aacagccacc cacacttgtg actatgcagg ctgtggcaaa acctatacga agagttetca 1320 teteaaggea cacetgegaa eteacaeagg egagaaacet taceaetgtg aetgggaegg 1380 20 ctgtgggtgg aaattegece geteagatga actgaceagg cactacegea aacaeeegg 1440 gcaccggccc tttcagtgcc agaagtgcga cagggccttt tccaggtcgg accaccttgc 1500 cttacacatg aagaggcact tttaaattcc acatcgtgga catgacccac actgccagga 1560 gagagttcag tattttttt taacctttca cactgtcttc ccacgagggg aggagcccag 1620 ctggcaagcg ctacaatcat ggtcaagttc ccagcaagtc agcttgtgaa tggataatca 1680 25 caaacaaaaa aaaaaaacaa aagaaaaaaa tcacagaaca gatggggtct gagactggat 1800 cttctatcat tccaatacca aatccgactt gaacaagact ggacttacaa aatgccaagg 1860 ggtgactgga agtttgtgga tatcagggta tacattaaat cagtgacctg ggggggaggga 1920 agaccagagt tcccttgaat tgtgcttcaa tgatgcaata tacatggaaa gaccaccttg 1980 tatgctcttt gccttctaaa aagccattat gacgtcagag gaagaggaag caattcaggt 2040 30 acagaacgtg ttctaatagc ctaaacgatg gtgcttggtg agtcgtggtt ctaaaggtac 2100 caaacggggg agccaaagtt ctccaactgc tgcatacttt gacaaggaaa atctatttt 2160 gtcttccgat ctacatttat gacctaagtc aggtaaataa gcctggttta tttctgtaac 2220 attttttatg cagacagtct gttatgcact gtggtttcag atgtgcaata atttgtacaa 2280 tggtttattc ccaagtatgc ctttaagcag aacaaatgtg tttttctata tagttccttg 2340 35 2393 <210> 12 <211> 4018 <212> DNA <213> Homo sapiens 40 <400> 12 caggcagcgc tgcgtcctgc tgcgcacgtg ggaagccctg gccccggcca cccccgcgat 60 geogegeget ecception gageogtgeg etcectgetg egcagecaet acceptgagt 120 gctgccgctg gccacgttcg tgcggcgcct ggggccccag ggctggcggc tggtgcagcg 180 cggggacccg gcggctttcc gcgcgctggt ggcccagtgc ctggtgtgcg tgccctggga 240 cgcacggccg ccccccgccg ccccctctt ccgccaggtg tcctgcctga aggagctggt 300 45 ggcccgagtg ctgcagaggc tgtgcgagcg cggcgcgaag aacgtgctgg ccttcggctt 360 cgcgctgctg gacgggggccc gcggggggccc ccccgaggcc ttcaccacca gcgtgcgcag 420 ctacctgccc aacacggtga ccgacgcact gcgggggggg gggcgtggg ggctgctgct 480 gcgccgcgtg ggcgacgacg tgctggttca cctgctggca cgctgcgcgc tctttgtgct 540 ggtggctccc agctgcgcct accaggtgtg cgggccgccg ctgtaccagc tcggcgctgc 600 50 cactcaggcc cggcccccgc cacacgctag tggaccccga aggcgtctgg gatgcgaacg 660 ggcctggaac catagcgtca gggaggccgg ggtccccctg ggcctgccag ccccgggtgc 720 gaggaggcgc gggggcagtg ccagccgaag tctgccgttg cccaagaggc ccaggcgtgg 780 cgctgcccct gagccggagc ggacgcccgt tgggcagggg tcctgggccc acccgggcag 840 gacgcgtgga ccgagtgacc gtggtttctg tgtggtgtca cctgccagac ccgccgaaga 900

ctgggccccc acattaatga ggcagccacc tggcgagtct gacatggctg tcagcgacgc 120 tctgctcccg tccttctcca cgttcgcgtc cggcccggcg ggaagggaga agacactgcg 180

agccacctct ttggagggtg cgctctctgg cacgcgccac tcccacccat ccgtgggccg 960

ccagcaccac gcggggccccc catccacatc gcggccacca cgtccctggg acacgccttg 1020 tcccccggtg tacgccgaga ccaagcactt cctctactcc tcaggcgaca aggagcagct 1080

ggagaccatc tttctgggtt ccaggccctg gatgccaggg actccccgca ggttgccccg 1200 cctgccccag cgctactggc aaatgcggcc cctgtttctg gagctgcttg ggaaccacgc 1260 gcagtgcccc tacggggtgc tcctcaagac gcactgcccg ctgcgagctg cggtcacccc 1320 agcagccggt gtctgtgccc gggagaagcc ccagggctct gtggcggccc ccgaggagga 1380 ggacacagac ccccgtcgcc tggtgcagct gctccgccag cacagcagcc cctggcaggt 1440 gtacggette gtgegggeet geetgegeeg getggtgeee eeaggeetet ggggeteeag 1500 gcacaacgaa cgccgcttcc tcaggaacac caagaagttc atctccctgg ggaagcatgc 1560 caageteteg etgeaggage tgacgtggaa gatgagegtg egggaetgeg ettggetgeg 1620 caggagccca ggggttggct gtgttccggc cgcagagcac cgtctgcgtg aggagatcct 1680 ggccaagttc ctgcactggc tgatgagtgt gtacgtcgtc gagctgctca ggtctttctt 1740 ttatgtcacg gagaccacgt ttcaaaagaa caggctcttt ttctaccgga agagtgtctg 1800 gagcaagttg caaagcattg gaatcagaca gcacttgaag agggtgcagc tgcgggagct 1860 gtcggaagca gaggtcaggc agcatcggga agccaggccc gccctgctga cgtccagact 1920 ccgcttcatc cccaagcctg acgggctgcg gccgattgtg aacatggact acgtcgtggg 1980 agccagaacg ttccgcagag aaaagagggc cgagcgtctc acctcgaggg tgaaggcact 2040 gttcagcgtg ctcaactacg agcgggcgcg gcgccccggc ctcctgggcg cctctgtgct 2100 gggcctggac gatatccaca gggcctggcg caccttcgtg ctgcgtgtgc gggcccagga 2160 cccgccgcct gagctgtact ttgtcaaggt ggatgtgacg ggcgcgtacg acaccatccc 2220 ccaggacagg ctcacggagg tcatcgccag catcatcaaa ccccagaaca cgtactgcgt 2280 gcgtcggtat gccgtggtcc agaaggccgc ccatgggcac gtccgcaagg ccttcaagag 2340 ccacgtctct accttgacag acctccagcc gtacatgcga cagttcgtgg ctcacctgca 2400 ggagaccagc ccgctgaggg atgccgtcgt catcgagcag agctcctccc tgaatgaggc 2460 cagcagtggc ctcttcgacg tcttcctacg cttcatgtgc caccacgccg tgcgcatcag 2520 gggcaagtcc tacgtccagt gccaggggat cccgcagggc tccatcctct ccacgctgct 2580 ctgcagcctg tgctacggcg acatggagaa caagctgttt gcgggggattc ggcgggacgg 2640 aacctteete aggaeeetgg teegaggtgt eeetgagtat ggetgegtgg tgaacttgeg 2760 gaagacagtg gtgaacttcc ctgtagaaga cgaggccctg ggtggcacgg cttttgttca 2820 gatgccggcc cacggcctat tcccctggtg cggcctgctg ctggataccc ggaccctgga 2880 ggtgcagagc gactactcca gctatgcccg gacctccatc agagccagtc tcaccttcaa 2940 ccgcqgcttc aaggctggga ggaacatgcg tcgcaaactc tttggggtct tgcggctgaa 3000 gtgtcacagc ctgtttctgg atttgcaggt gaacagcctc cagacggtgt gcaccaacat 3060 ctacaagatc ctcctgctgc aggcgtacag gtttcacgca tgtgtgctgc agctcccatt 3120 tcatcagcaa gtttggaaga accccacatt tttcctgcgc gtcatctctg acacggcctc 3180 cctctgctac tccatcctga aagccaagaa cgcagggatg tcgctgggggg ccaagggcgc 3240 cgccggccct ctgccctccg aggccgtgca gtggctgtgc caccaagcat tcctgctcaa 3300 gctgactcga caccgtgtca cctacgtgcc actcctgggg tcactcagga cagcccagac 3360 gcagctgagt cggaagetee cggggacgae getgactgee etggaggeeg cagecaacee 3420 ggcactgccc tcagacttca agaccatcct ggactgatgg ccacccgccc acagccaggc 3480 cgagagcaga caccagcagc cctgtcacgc cgggctctac gtcccaggga gggaggggcg 3540 gcccacaccc aggcccgcac cgctgggagt ctgaggcctg agtgagtgtt tggccgaggc 3600 ctgcatgtcc ggctgaaggc tgagtgtccg gctgaggcct gagcgagtgt ccagccaagg 3660 getgagtgte cageacacet geegtettea ettececaea ggetggeget eggetecaee 3720 ccagggccag cttttcctca ccaggagccc ggcttccact ccccacatag gaatagtcca 3780 tecccagatt egecattgtt caccectege cetgecetee tttgeettee acceceacea 3840 tccaqqtqqa qaccctqaqa aqqaccctqq qaqctctqqq aatttqqaqt qaccaaaqqt 3900 gtgccctgta cacaggcgag gaccctgcac ctggatgggg gtccctgtgg gtcaaattgg 3960 ggggaggtgc tgtgggagta aaatactgaa tatatgagtt tttcagtttt gaaaaaaa 4018 <210> 13 <211> 4237 <212> DNA <213> Mus musculus <400> 13 ggttcccgca cgtgggaggc ccatcccggc cttgagcaca atgacccgcg ctcctcgttg 60

EP 2 881 461 A1

gcggccctcc ttcctactca gctctctgag gcccagcctg actggcgctc ggaggctcgt 1140

5

10

15

20

25

30

35

40

45

50

55

ccccgcggtg cgctctctgc tgcgcagccg ataccgggag gtgtggccgc tggcaacctt 120 tgtgcggcgc ctggggcccg agggcaggcg gcttgtgcaa cccggggacc cgaagatcta 180 ccgcactttg gttgcccaat gcctagtgtg catgcactgg ggctcacagc ctccacctgc 240 cgacctttcc ttccaccagg tgtcatccct gaaagagctg gtggccaggg ttgtgcagag 300 actctgcgag cgcaacgaga gaaacgtgct ggcttttggc tttgagctgc ttaacgaggc 360

cagaggcggg cctcccatgg ccttcactag tagcgtgcgt agctacttgc ccaacactgt 420 tattgagacc ctgcgtgtca gtggtgcatg gatgctactg ttgagccgag tgggcgacga 480

ctaccaggtg tgtgggtctc ccctgtacca aatttgtgcc accacggata tctggccctc 600 tgtgtccgct agttacaggc ccacccgacc cgtgggcagg aatttcacta accttaggtt 660 cttacaacag atcaagagca gtagtcgcca ggaagcaccg aaacccctgg ccttgccatc 720 tcgaggtaca aagaggcatc tgagtctcac cagtacaagt gtgccttcag ctaagaaggc 780 cagatgctat cctgtcccga gagtggagga gggaccccac aggcaggtgc taccaacccc 840 atcaggcaaa tcatgggtgc caagtcctgc tcggtccccc gaggtgccta ctgcagagaa 900 agatttgtct tctaaaggaa aggtgtctga cctgagtctc tctgggtcgg tgtgctgtaa 960 acacaagccc agctccacat ctctgctgtc accaccccgc caaaatgcct ttcagctcag 1020 gccatttatt gagaccagac atttccttta ctccagggga gatggccaag agcgtctaaa 1080 cccctcattc ctactcagca acctccagcc taacttgact ggggccagga gactggtgga 1140 gatcatcttt ctgggctcaa ggcctaggac atcaggacca ctctgcagga cacaccgtct 1200 atcgcgtcga tactggcaga tgcggcccct gttccaacag ctgctggtga accatgcaga 1260 gtgccaatat gtcagactcc tcaggtcaca ttgcaggttt cgaacagcaa accaacaggt 1320 gacagatgcc ttgaacacca gcccaccgca cctcatggat ttgctccgcc tgcacagcag 1380 tccctggcag gtatatggtt ttcttcgggc ctgtctctgc aaggtggtgt ctgctagtct 1440 ctggggtacc aggcacaatg agcgccgctt ctttaagaac ttaaagaagt tcatctcgtt 1500 ggggaaatac ggcaagctat cactgcagga actgatgtgg aagatgaaag tagaggattg 1560 ccactggctc cgcagcagcc cggggaagga ccgtgtcccc gctgcagagc accgtctgag 1620 ggagaggatc ctggctacgt tcctgttctg gctgatggac acatacgtgg tacagctgct 1680 taggtcattc ttttacatca cagagagcac attccagaag aacaggctct tcttctaccg 1740 taagagtgtg tggagcaagc tgcagagcat tggagtcagg caacaccttg agagagtgcg 1800 gctacgggag ctgtcacaag aggaggtcag gcatcaccag gacacctggc tagccatgcc 1860 catctgcaga ctgcgcttca tccccaagcc caacggcctg cggcccattg tgaacatgag 1920 ttatagcatg ggtaccagag ctttgggcag aaggaagcag gcccagcatt tcacccagcg 1980 teteaagaet etetteagea tgeteaacta tgageggaea aaacateete acettatggg 2040 gtcttctgta ctgggtatga atgacatcta caggacctgg cgggcctttg tgctgcgtgt 2100 gcgtgctctg gaccagacac ccaggatgta ctttgttaag gcagatgtga ccggggccta 2160 tgatgccatc ccccagggta agctggtgga ggttgttgcc aatatgatca ggcactcgga 2220 gagcacgtac tgtatccgcc agtatgcagt ggtccggaga gatagccaag gccaagtcca 2280 caagteettt aggagacagg teaceacect etetgacete cagecataca tgggecagtt 2340 ccttaagcat ctgcaggatt cagatgccag tgcactgagg aactccgttg tcatcgagca 2400 gagcatctct atgaatgaga gcagcagcag cctgtttgac ttcttcctgc acttcctgcg 2460 tcacagtgtc gtaaagattg gtgacaggtg ctatacgcag tgccagggca tcccccaggg 2520 ctccagccta tccaccctgc tctgcagtct gtgtttcgga gacatggaga acaagctgtt 2580 tgctgaggtg cagcgggatg ggttgctttt acgttttgtt gatgactttc tgttggtgac 2640 gcctcacttg gaccaagcaa aaaccttcct cagcaccctg gtccatggcg ttcctgagta 2700 tgggtgcatg ataaacttgc agaagacagt ggtgaacttc cctgtggagc ctggtaccct 2760 gggtggtgca gctccatacc agctgcctgc tcactgcctg tttccctggt gtggcttgct 2820 gctggacact cagactttgg aggtgttctg tgactactca ggttatgccc agacctcaat 2880 taagacgagc ctcaccttcc agagtgtctt caaagctggg aagaccatgc ggaacaagct 2940 cctgtcggtc ttgcggttga agtgtcacgg tctatttcta gacttgcagg tgaacagcct 3000 ccagacagtc tgcatcaata tatacaagat cttcctgctt caggcctaca ggttccatgc 3060 atgtgtgatt cagctteeet ttgaccageg tgttaggaag aaceteacat tetttetggg 3120 catcatetee agecaageat cetgetgeta tgetateetg aaggteaaga atecaggaat 3180 gacactaaag gcctctggct cctttcctcc tgaagccgca cattggctct gctaccaggc 3240 cttcctgctc aagctggctg ctcattctgt catctacaaa tgtctcctgg gacctctgag 3300 gacagcccaa aaactgctgt gccggaagct cccagaggcg acaatgacca tccttaaagc 3360 tgcagctgac ccagccctaa gcacagactt tcagaccatt ttggactaac cctgtctcct 3420 tccgctagat gaacatgggc attgtagcct cagcactcct ggatccacgt cacaagaggg 3480 actggtcagt tgtgaggcta ggtcatcctc caaacctctg tgtcatgggt ggtatgggag 3540 attgtcccag tgccttgttt cctgtaacag gcttgatttc tttcctgatg ccctcaggga 3600

cctgctggtc tacctgctgg cacactgtgc tctttatctt ctggtgcccc ccagctgtgc 540

5

10

15

20

25

30

35

40

45

50

55

ggcagateet ateeettta gtggcaggga teeactagea ceageacatg aggagtgeae 3660 ceagtgeaca tgggeaetgg gacagtggae aggtgtgaga tteetgggee etggagtett 3720 tteacaceta accatggage etgteeeagt acateagagt geeteggaga tgaaaaagga 3780

catcgagcca gtgacctaaa ttacagcctg aatatactct gaattcatgt gactgcctta 3840 gctacttctc tactgctgtg tagtaaaaca ccaagccaac ttataaaagc aggatttcc 3900 tactggagca gcagctgaga gtttacatct tgatccataa gcacaaaagc acaagacaga 3960 gagagagaga gagagagaga gagagagaga gagagagaga gagagagaga gagagagtca 4020 gtcagtcagt ctaacaaata actaagaaag gtgaagggtg atgaagtcca cagggatcac 4080 gctagggatg ttccatgcct tctctgaagc taagattcct tggcagcgtt tgacagtaac 4140

catagtgggt acctactgag atcactataa agataaaata gggggaagcg tatttgtact 4200

4237

gaactggaaa aacatacaaa taaagagtaa atcatgg

	<210> 14						
	<211> 3378						
	<212> DNA						
	<213> Rattu	us norvegicu	ıs				
5	<400> 14						
	atgccccgcg	ctcctcgttg	ccccgccgtg	cgctctctac	tgcgcagccg	atatcgggag	60
	gtgtggccgc	tggcgacctt	tgtgcggcgc	ctggggcttg	agggcagtcg	gcttgtgcaa	120
	cccggggacc	cgaaggtctt	ccgcacgttg	gttgcccagt	gcctagtgtg	cgtgccctgg	180
	ggctcacagc	cgccacctgc	tgacctttcc	ttccaccagg	tgtcatccct	gaaagagctg	240
	gtgtccaggg	ttgtgcagaa	actttgcgag	cgcggtgaga	ggaatgtgct	ggcttttggc	300
10	tttgcactgc	ttaacggggc	cagaggtggg	cctcccatgg	ccttcacgac	cagcgtgcat	360
	agctacttgc	ccaactcggt	tactgagtcc	ctgtgtgtca	gtggtgcatg	gatgctactg	420
	ttgagccgag	tgggcgacga	cctgctggtc	tacctgctgt	cgcactgtgc	gctctacctg	480
	ctggtgcccc	ccagctgtgc	ctaccaggtg	tgcgggtcac	ccctgtacca	aatttgtgcc	540
	accacggata	cctggtcctc	tgtgcccgct	ggttacaggc	ccactcgacc	cgtgggcggg	600
15	aatttcacta	accttgggtc	cgcacaccag	atcaaaaaca	gtggtcacca	ggaagcacca	660
	aaaccccagg	ccttgccatc	acgaggtacg	aagaggcttc	tgagtctcac	cagtacaaac	720
	gtgccttcag	ctaagaaggc	caggtttgaa	cctgccctga	gagtggataa	gggaccccac	780
	aggcaggtgg	taccaacccc	atcaggcaaa	acatgggcgc	caagtcctgc	tgcgtccccc	840
						cccgagtctc	
	tctgggtcgg	tgtgctgtaa	acacaagccc	agctcctcgt	ccctgctgtc	atcaccaccc	960
20	caagatgctg	aaaagctcag	gccattcact	gagaccagac	atttccttta	ctccagggga	1020
	ggtggccaag	aggagctaaa	tccctcattc	ctactcaaca	gcctcccgcc	tagcttgacc	1080
	ggggccagga	gactggtgga	gatcatcttt	ctgggctcaa	ggcctaggac	atcaggacca	1140
	ttctgcagga	cccgccgcct	gccccgtcga	tactggcaga	tgcgacccct	attccagcag	1200
						ctgcagattt	
25	cgaacagcaa	accagcgggt	gccggatgcc	atggacacca	gcccatccca	cctcacgagt	1320
	ttgctccggt	tacacagcag	cccctggcag	gtatacggct	ttcttcgggc	ctgcctccgc	1380
	gagctggtgc	ctgccggtct	ctggggcacc	aggcacaatg	agcgccgctt	cttaaagaac	1440
	gtgaagaagt	tcatctcgtt	ggggaagtac	gccaagctat	ccctgcagga	actgatgtgg	1500
						cactgtccct	
						gctaatggac	
30						gttccagaag	
						tggaatcagg	
						gcatcaccag	
						caatggtctc	
						aaagaagcag	
35						cgagcggacc	
						caggatctgg	
						ctttgttaag	
						aattgtcgcc	
						ggttcagaaa	
10						ctctgacctc	
40						tgcactgagg	
						cctgctccac	
						ctatgtgcaa	
						gtgtttcgga	
						acgttttgtc	
45						cagcaccctg	
						ggtgaacttc	
						tcactgcctg	
						tgactactca	
						cagggccggg	
50						tctgtttcta	
50						cttcctgctt	
						tgttaggaag	
						cgccatcctg	
						ctttccgccc	
						tcattctgtc	
55						ccggaagctc	
			CCTTAAGACT	gcagetgace	cagccctaag	cacagatttt	
	cagaccattt	tggactaa					3378

	<210> 15						
	<211> 1903						
	<212> DNA						
	<213> Homo	sapiens					
5	<400> 15						
	cggcgtcccc	ggggcccact	cccgagcgca	ggcgggcagc	caggcgggcg	gcgcggcgcg	60
	ggccggcagg	aagcgtattc	tgggcacggg	gcgccgggcg	ggccggctgc	gccgagcggc	120
			ggcctcgcgc				
			gagcgcagga				
			tgctgcgtgc				
10			tttccaaagg				
			agtgggtgct				
			cagggcggcc				
			aatgagcgca				
			cagcaacagc				
15			cagcagcagc				
			cagccgaacc				
			agcagtcagg				
			aagcccatcg				
			gccgccgcgt				
			ggcccccagt				
20			tactccttgt				
			gacatcctgg				
			cgtctcactg				
			gctgtcatcc				
			agaccccatc				
25			tggttgacag				
20			aattgtttcc				
			ttatgacttt				
			ttcagaacca				
			ataggtttgg				
			agtgataaga				
30			gcagcctgtg				
	ctgcctccta	ggacttattt	tcccaggagg	ccatttacaa	ggggatctgg	atgacctgct	1740
	gatggagatc	cagettgeca	gggacttagg	tttatcctgt	tttgtttgct	actggttaca	1800
	aattctattt	tctgtacaat	tagtcagact	aaagttttca	ctgtgtttgt	ttggcaaaac	1860
	aaattaaaca	aaaagtaagg	tttttaaaaa	aaaaaaaaaa	aaa		1903
35							
55	<210> 16						
	<211> 1832						
	<212> DNA						
	<213> Mus m	nusculus					
	<400> 16						
40	gaagcgcagg	cggacggccg	ggtgggtagc	agcggcgcgg	gcggtccgca	accatattct	60
	gggcacgggg	cctcggcccg	ggacgactgc	gccgggcggc	aatagtgaga	ggcctctgag	120
	agcctcgcgc	ggcgccgccc	gtcgaggagc	tgagacaggg	gccagacccg	gccgtcgaag	180
	agctcgagag	gccggtgggc	cgggccgcgc	gtcgcagcca	tgcctggctt	tacgtgctgc	240
			ttcacaccgg				
45	aaggacgctg	agttgcggcg	cctctggctc	aagaacgtgt	cccgtgctgg	cgtcagtggg	360
40	tgcttctcca	ccttccaacc	caccaccggc	caccgtctct	gcagcgtcca	ctttcagggc	420
			gcgcgttccc				
	cgcaaagtag	ctcggagacc	tgcgggagct	gcggcagccc	gccgtaggca	gcagcagcag	540
			gcaacagcag				
	tcctccactg	cccagaccac	ccagttgcag	ccgaacctgg	tgtctgcctc	tgcagctgtg	660
50			cgtagacagc				
			tgatgtgaag				
			cgccgctgcc				
	gggctggagg	ccgctgagtg	cactctgggc	cctcagctgg	tggtggtagg	ggaagagggc	900
			ccactcgtac				
55			gcagcgggac				
55			ccatctgcgt				
			tgccatggct				

5 10	gttcccccca gaaacctgca gaattcgtga ctccttccag cccaaggaat cctcaggcaa atgttgtact ccccagtatt cctgttgaca gtgccgaggt ttaggacagc gggactccag gtggtgacacc agcagttatg actttgtcc tcactcccca gtttatgttg cagattctgg ttatacacag gcttcagaac cactgaactt ggaacttacc ctggaggggg tgcagatgga actcttaagg gactgtgggt ttgaggaac cactcttca ggttggccag caatcagaga cagctttgct gtgtgtagtg ataagagac tcagtaacat cgtttctcct ttccatgcta taggacccc ccagggactt aggtcattat gggcattac cgtgadgg tgcagtcg caggttcag gtgcagtcg tgattctgat ggggactagc tggtggcag catcaggag atccagcta ccagggactt aggttatct cgttatgtt gctgatggag accaggtcag aggtatta aaaaaggcc cgttatgtt gctactggt acaaattca aaggttttta aaaaaaaaa aaaaggcca ca	1260 1320 1380 1440 1500 1560 1620 1680 1740
15	<210> 17 <211> 55 <212> DNA <213> Escherichia coli <400> 17 tctagagcgg ccgcccggcg ggtcgccacc atgagtgtgg atccagcttg tcccc	55
20	<210> 18 <211> 36 <212> DNA <213> Escherichia coli <400> 18	36
25	<pre>catgcaacct gaagacgtgt gaagactagt atcgat <210> 19 <211> 51 <212> DNA <213> Escherichia coli <400> 19</pre>	30
30	<pre><400> 19 tctagagcgg ccgcccggcg ggtcgccacc atggctgtca gcgacgcgct g <210> 20 <211> 46</pre>	51
35	<212> DNA <213> Escherichia coli <400> 20 ccacctcgcc ttacacatga agaggcattt ttaaaagctt atcgat	46
40	<210> 21 <211> 50 <212> DNA <213> Escherichia coli <400> 21 tctagaggat ccccggcggg tcgccaccat ggcggccgcg ggaattcgat	50
45	<210> 22 <211> 39 <212> DNA <213> Escherichia coli <400> 22	
50	ggcacactgc ccctctcaca catgtgaaag cttatcgat <210> 23 <211> 51	39
55	<212> DNA <213> Escherichia coli <400> 23 tctagagcgg ccgcccggcg ggtcgccacc atggcgggac acctggcttc g	51
	<210> 24	

	<211> 37	
	<212> DNA	
	<213> Escherichia coli	
5		37
	gggctctccc atgcattcaa actgaggatc catcgat	51
	<210> 25	
	<211> 50	
	<212> DNA	
10	<213> Escherichia coli	
	<400> 25	
	tctagagcgg ccgcccggcg ggtcgccacc atgccgcgcg ctccccgctg	50
	<210> 26	
15	<211> 41	
	<212> DNA	
	<213> Escherichia coli <400> 26	
	caaaatccca agcgtggcgc tgcccttaaa agcttatcga t	41
	cadaleeea agegeggege egeeeltaaa ageelatega t	37
20	<210> 27	
	<211> 43	
	<212> DNA	
	<213> Escherichia coli	
	<400> 27	
25	tctagagcgg ccgcccggcg ggtcgccacc atggtgagca agg	43
	<210> 28	
	<211> 38	
	<212> DNA <213> Escherichia coli	
30	<213> Escherichia coll <400> 28	
	<pre><400> 20 ctcggcatgg acgagctgta caataaaagc ttatcgat</pre>	38
	cicyycalyy acyayolyta caalaaaayo ttaloyat	50

35 Claims

45

55

- 1. A process for preparing reprogrammed mammalian cells in vitro without the use of a virus, comprising
 - a) providing isolated mammalian cells to be reprogrammed,
- b) transfecting one or more reprogramming mRNA molecules into the cells provided in step a), wherein the reprogramming mRNA molecules are encoding at least one reprogramming protein selected from the group consisting of Ronin, Oct4, Klf4, Sox2, Nanog and TERT,

c) culturing the cells obtained in step b) in a cell culture medium and under a condition suitable to allow translation of the transfected reprogramming mRNA molecules, and wherein a condition suitable to allow translation of the transfected reprogramming mRNA molecules is a temperature from 30°C to 38°C and is an oxygen content in the cell culture medium from 0.5% to 21% and wherein the cell culture medium has a glucose content of 0.1 g/l to 4.6 g/l, so as to obtain reprogrammed cells, wherein said reprogrammed cells are mammalian cells exhibiting a pluripotent or multipotent stem cell character.

- 50 2. The process according to any one of the preceding claims, wherein the cell culture medium contains at least one inducing substance selected from the group consisting of reversine, resveratrol, selenium, selenium containing compounds, EGCG (epigallocatechin-3-gallate), valproic acid, salts of valproic acid and sodium valproate.
 - 3. The process according to any one of the preceding claims, wherein the cell culture medium contains at least one transient proteolysis inhibitor.
 - 4. The process according to claim 3, wherein the transient proteolysis inhibitor is selected from the group consisting of protease inhibitor, proteasome inhibitor and lysosome inhibitor.

EP 2 881 461 A1

- 5. The process according to any one of the preceding claims, wherein the cells to be reprogrammed are human cells.
- 6. A process for inducing the dedifferentiation of mammalian cells, wherein a process according to any one of claims 1 to 6 is carried out.
- 7. A process for improving the expansion of mammalian stem cells *in vitro*, wherein a process according to any one of claims 1 to 6 is carried out, comprising
 - a) providing isolated mammalian cells to be reprogrammed,
 - b) transfecting one or more reprogramming mRNA molecules into the cells provided in step a), wherein the reprogramming mRNA molecules are encoding at least one reprogramming protein selected from the group consisting of Ronin, Oct4, Klf4, Sox2, Nanog and TERT,
- c) culturing the cells obtained in step b) in a cell culture medium and under a condition suitable to allow translation of the transfected reprogramming mRNA molecules, and wherein a condition suitable to allow translation of the transfected reprogramming mRNA molecules is a temperature from 30°C to 38°C and is an oxygen content in the cell culture medium from 0.5% to 21% and wherein the cell culture medium has a glucose content of 0.1 g/l to 4.6 g/l, so as to obtain reprogrammed cells, wherein said reprogrammed cells are mammalian cells exhibiting a pluripotent or multipotent stem cell character,
 - wherein said culturing in step c) is **characterized by** prolonging expansion of the pluripotent or multipotent stem cells obtained, whereby said stem cells to be expanded are kept in a dedifferentiated status.
 - **8.** A process for the rejuvenation of aged mammalian cells, wherein a process according to any one of claims 1 to 6 is carried out.

25

5

10

15

20


30

35

45

- 50

55



Amaxa Elektroporation (klf4, sox2, oct4)





Fig. 2










Fig. 4

RT-PCR für Oct4



RT-PCR hOct4

Fig. 5






Fig. 7

yonaang Agaart Agaart Agaar Agaar Agaar 7 MIN 5 4000 KIE I Sox2_1 z zxos t Sxoz 1000 ocr4 2 1 200 25 200 儆 rapper 4000 - 0004 2000 - * ۱ کا parante des Can hannat RIN WA ф С Fig. 8 geronaty -djenor Cana horoverst 4000 4000 0ct4_1 kif4_2 1000 25 200 1000 200 25 RIN N/A RIN N/A entropionerania processory control con R noonna poarnaag noon noon hadour kanaard S \diamond

EP 2 881 461 A1



EUROPEAN SEARCH REPORT

Application Number EP 14 19 2115

		DOCUMENTS CONSID	ERED TO BE RELEVANT]		
40	Category	Citation of document with i of relevant pass	ndication, where appropriate, ages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)		
10	2 A	WO 2008/087442 A (E JOHNSON ANDREW [GB 24 July 2008 (2008 * page 33 - page 34 * page 6 *	INV. C12N5/071				
:	5 A	JAENISCH RUDOLF ET molecular circuitry nuclear reprogrammi CELL,					
20		vol. 132, no. 4, Fe pages 567-582, XP00 ISSN: 0092-8674 * the whole documer					
25	5 A	TAKAHASHI K ET AL: pluripotent stem ce embryonic and adult defined factors", CELL, CELL PRESS, (vol. 126, no. 4,	ells from mouse fibroblast cultures by	1-8	TECHNICAL FIELDS		
30		V01. 128, 10. 4, 25 August 2006 (200 663-676, XP00301396 ISSN: 0092-8674 * the whole documer	58,		C12N		
35	5 A	YU JUNYING ET AL: stem cell lines der cells", SCIENCE, AMERICAN A ADVANCEMENT OF SCIE vol. 318, no. 5858					
40		21 December 2007 (2 1917-1920, XP009105 ISSN: 1095-9203 * the whole documer	2007-12-21), pages 5055, nt *				
45			-/	-			
	2	The present search report has					
50	[]]	Place of search Date of completion of the sear Munich 28 March 2015		Examiner Paresce, Donata			
	X:par X:par Y:par doc	ATEGORY OF CITED DOCUMENTS ticularly relevant if taken alone ticularly relevant if combined with anot ument of the same category nological background	T : theory or principle E : earlier patent doc after the filing dat her D : document cited ir L : document cited fo	T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons			
55	O : nor D P : inte	n-written disclosure rmediate document		& : member of the same patent family, corresponding			

5



5

EUROPEAN SEARCH REPORT

Application Number EP 14 19 2115

	F		Citation of document with in	dication, where appropriate,	Relevant	CLASSIFICATION OF THE	
<u> </u>	C	Category	of relevant passa		to claim	APPLICATION (IPC)	
0	2	A	WO 2008/097926 A (UNIV YALE [US]; RABINOVICH PETER M [US]; WEISSMAN SHERMAN M [US]; KOMA) 14 August 2008 (2008-08-14) * page 1 - page 5 *				
5	5	A	DEJOSEZ MARION ET AL: "Ronin is essential 1 for embryogenesis and the pluripotency of mouse embryonic stem cells (vol 133, pg 1162, 2008)", CELL,				
0			vol. 134, no. 4, Au page 692, XP0091146 ISSN: 0092-8674 * page 1168 - page				
5	6	A	ZUK P A ET AL: "Human adipose tissue is a 1 source of multipotent stem cells", MOLECULAR BIOLOGY OF THE CELL, AMERICAN SOCIETY FOR CELL BIOLOGY, US, vol. 13, no. 12,				
0			20 December 2002 (2 4279-4295, XP002249 ISSN: 1059-1524, D0 10.1091/MBC.E02-02- * the whole documen	630, I: 0105		TECHNICAL FIELDS SEARCHED (IPC)	
5	6	A	JULIANE M. WIEHE ET AL: "mRNA-Mediated Gene Delivery Into Human Progenitor Cells Promotes Highly Efficient Protein Expression", JOURNAL OF CELLULAR AND MOLECULAR MEDICINE,		1-8		
)			vol. 11, no. 3, 1 M pages 521-530, XP05 ISSN: 1582-1838, D0 10.1111/j.1582-4934 * the whole documen	I: .2007.00038.x			
5				-/			
	2		The present search report has t	peen drawn up for all claims Date of completion of the search	 	Examiner	
50			Munich	28 March 2015		Paresce, Donata	
	(P04C						
1503 03.82 (P04C01)		X : part Y : part docu	ATEGORY OF CITED DOCUMENTS icularly relevant if taken alone icularly relevant if combined with anot iment of the same category	E : earlier patent doc after the filing date ner D : document cited in L : document cited fo	T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons		
5	EPO FORM	O : non	nological background -written disclosure rmediate document	& : member of the sa document	me patent family	/, corresponding	



5

EUROPEAN SEARCH REPORT

Application Number EP 14 19 2115

	ſ					7	
			DOCUMENTS CONSIDE	ERED TO BE RELEVANT	F · · · · · · · · · · · · · · · · · · ·		
		Category	Citation of document with in of relevant passa	dication, where appropriate, ges	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)	
0	6	A	CHUNG YOUNG ET AL: "Human embryonic stem 1 cell lines generated without embryo destruction", CELL STEM CELL, ELSEVIER, CELL PRESS, AMSTERDAM, NL,				
5 0			vol. 2, no. 2, 7 February 2008 (200 113-117, XP00260469 ISSN: 1934-5909, D0 10.1016/J.STEM.2007 * the whole document	6, I: .12.013			
5					1 0		
	2	E	WO 2009/077134 A2 (U GUTENBERG [DE]; SAH MARCO [) 25 June 200 * the whole documen	IN UGUR [DE]; POLEGANOV 09 (2009-06-25)	1-8		
5	2	-	Un 2000/002022 A2 (I	UNIV SHEFFIELD [GB]; NA	1_8		
	2	E	UIE [GB]; ANDREWS PI 30 July 2009 (2009-(* the whole document	ETER [GB]) 97-30)	1-0	TECHNICAL FIELDS	
•						SEARCHED (IPC)	
0	6	Т	ISRN CELL BIOLOGY,,	"Reprogramming of broblasts Using mRNA", y 2012 (2012-01-01),			
5							
0							
5							
	2		The present search report has b	een drawn up for all claims			
			Place of search	Date of completion of the search		Examiner	
50 50		Munich		28 March 2015	March 2015 Paresce, D		
	32 (PC	C	ATEGORY OF CITED DOCUMENTS	T : theory or principle	underlying the i	nvention	
	EPO FORM 1503 03.82 (P04C01)	Y:part docu	icularly relevant if taken alone icularly relevant if combined with anoth ument of the same category pedegical background	after the filing date er D : document cited in L : document cited fo	E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons		
	E	A : technological background O : non-written disclosure P : intermediate document			& : member of the same patent family, corresponding document		

EP 2 881 461 A1

ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 14 19 2115

5

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

28-03-2015

	Patent docum cited in search r	report	Publication date	Patent family member(s)	Publication date
	WO 2008087	442 A	24-07-2008	NONE	
	WO 2008097	926 A	14-08-2008	US 2008260706 A1 WO 2008097926 A2	23-10-2008 14-08-2008
	WO 2009077	134 A2	25-06-2009	DK 2240572 T3 EP 2072618 A1 EP 2240572 A2 ES 2532125 T3 JP 2011505814 A US 2011065103 A1 WO 2009077134 A2	09-03-2015 24-06-2009 20-10-2010 24-03-2015 03-03-2011 17-03-2011 25-06-2009
	WO 2009093	022 A2	30-07-2009	NONE	
		·			·
FORM P0459					

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

• US 200710254884 A1 [0005]

• US 200710020759 A1 [0005]

Non-patent literature cited in the description

- OKITA et al. *Science*, 07 November 2008, vol. 322 (5903), 949-53 [0003]
- ALTSCHUL, S.F. et al. J. Mol. Biol., 1990, vol. 215, 403 [0024]
- ALTSCHUL, S.F. et al. *Nucleic Acid Res.*, 1997, vol. 25, 3389-3402 [0024]
- AUSUBEL et al. Current Protocols in Molecular Biology. John Wiley & Sons Inc, 1994 [0030]